EP0655060A1 - Pharmaceutically active diketopiperazines - Google Patents

Pharmaceutically active diketopiperazines

Info

Publication number
EP0655060A1
EP0655060A1 EP93918032A EP93918032A EP0655060A1 EP 0655060 A1 EP0655060 A1 EP 0655060A1 EP 93918032 A EP93918032 A EP 93918032A EP 93918032 A EP93918032 A EP 93918032A EP 0655060 A1 EP0655060 A1 EP 0655060A1
Authority
EP
European Patent Office
Prior art keywords
piperazinedione
benzylidene
compound
methoxybenzylidene
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP93918032A
Other languages
German (de)
French (fr)
Other versions
EP0655060B1 (en
Inventor
Mark Anthony David 240 Bath Road Collins
Maria Inês 240 Bath Road CHICARELLI-ROBINSON
Justin Stephen 240 Bath Road Bryans
Stephen James 240 Bath Road Brocchini
Christopher John 240 Bath Road Latham
John Richardson 240 Bath Road Shaw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xenova Ltd
Original Assignee
Xenova Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xenova Ltd filed Critical Xenova Ltd
Publication of EP0655060A1 publication Critical patent/EP0655060A1/en
Application granted granted Critical
Publication of EP0655060B1 publication Critical patent/EP0655060B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Definitions

  • the present invention provides the use of a diketopiperazine of formula (A) :
  • each of R., to R 10 is independently selected from hydrogen, C,-C 6 alkyl unsubstituted or substituted by one or more halogen atoms, C 1 -C 6 alkoxy, C 1 -C 6 alkylthio, halogen, hydroxy, nitro, optionally substituted phenyl, cyano, -CH 2 OH, -CH 2 COOH, -C0 2 R 11 , -NHCOR 11 , -NHS0 2 R 13 , -S0 2 R 13 , -C0N(R 11 R 12 ) , -SOR 13 , -S0 2 N(R 11 R 12 ) , -N(R 11 R 12 ), -0 (CH 2 ) n N (R 11 R 12 ) , -0(CH 2 ) n C0 2 R 11 , -0C0R 11 , -CH 2 NHC0R 11 , -CH
  • one of rings a and b is unsubstituted or is mono-substituted whilst the other ring is unsubstituted or is substituted at one or more of positions 2 to 6.
  • the ring which is mono-substituted may carry the substituent at any one of positions 2 to 6, for instance position 3 or 4, especially position 4.
  • one of R 6 to R 10 is other than hydrogen, preferably R 7 or R g , especially R g .
  • one of R, to j is other than hydrogen, preferably R 2 or R 3 , especially R 3 .
  • the substituent R, to R j , or R 6 to R 10 respectively is preferably selected from a halogen, for instance fluorine; an alkoxy group, for instance OMe; and an acetamido group -NHAc in which Ac denotes acetyl.
  • the other ring may bear any desired substitution pattern. For instance, the other ring may be unsubstituted or may be mono-, di- or tri-substituted at any of positions 2 to 6.
  • the said other ring may, for instance, be mono- substituted at any of positions 2 to 6. It may also be 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5- disubstituted, or 2,3,4-, 2,3,5-, 2,3,6- or 3,4,5-trisubstituted.
  • R 1 to R j when the said other ring is a and is mono-substituted, four of R 1 to R j are hydrogen and one is other than hydrogen.
  • three - A - of R- to R j are hydrogen and two are other than hydrogen.
  • R, and R 2 , or R 1 and R 3 , or R 1 and R , or R, and R j , or R 2 and R 3 , or R 2 and R 4 are other than hydrogen whilst, in each case, the other three of R, to R j are hydrogen.
  • R 1 to R j are hydrogen and three are other than hydrogen.
  • R,, R 2 and R 3 , or R,, R 2 and R 4 , or R ⁇ R 2 and R j , or R 2 , R 3 and R 4 are other than hydrogen whilst, in each case, the other two of R, to R j are hydrogen.
  • R 6 to R 10 When the said ring is b and is mono-substituted, four of R 6 to R 10 are hydrogen and one is other than hydrogen. When the said other ring is b and is di-substituted, three of R 6 to R 10 are hydrogen and two are other than hydrogen.
  • R 6 and R 7 , or R 6 and R g , or R 6 and R,, or R 6 and R 10 , or R 7 and R g , or R 7 and R, are other than hydrogen whilst, in each case, the other three of R 6 to R 10 are hydrogen.
  • the said other ring When the said other ring is b and is trisubstituted, two of R 6 to R 10 are hydrogen and three are other than hydrogen.
  • R 6 , R 7 and R g , or R 6 , R 7 and R ⁇ ,, or R 6 , R 7 and R 10 , or R 7 , R g and R-, are other than hydrogen whilst, in each case, the other two of R 6 to R 10 are hydrogen.
  • any two adjacent substituents in the said other ring may, together with the carbon atoms to which they are attached, complete a second benzene ring which is optionally substituted, thus forming an optionally substituted naphthyl group with the said other ring.
  • R 1 and R 2 may form together with carbon atoms 2 and 3, or 3 and 4 respectively, an optionally substituted benzene ring which, in turn, forms with ring a a naphthyl group which i ⁇ unsubstituted or substituted by one or more groups specified above for R 1 to R 10 .
  • R 6 and R 7 or R 7 and R g may form, together with carbon atoms 2 and 3 or 3 and 4 respectively, an optionally substituted benzene ring which, in turn, forms with ring b a naphthyl group which is unsubstituted or substituted by one or more groups specified above for R, to R 10 .
  • the naphthyl group in either case is unsubstituted or is monosubstituted at position 1,2,3 or 4 of the naphthalene ring structure, especially position 4.
  • each of R 6 to R 10 is hydrogen.
  • one of R 6 to R 10 is selected from alkoxy, NHCOR 1 and halogen and the other four of R 6 to R 10 are H.
  • Alkoxy may be, for instance, OMe or 0Bu n .
  • NHCOR 11 is typically - NHAc.
  • Halogen is typically F or Cl.
  • R g is alkoxy, especially OMe or 0Bu n ; NHCOR 11 , especially -NHAc; or halogen, especially F or Cl; and each of R 6 , R 7 , , and R 10 is H.
  • R, to R j are all hydrogen, or one or two of R 1 to R j are other than hydrogen whilst the others are hydrogen.
  • R 1f R 2 and R 3 is other than hydrogen.
  • R 1 and R 3 , or R 2 and R 3 are other than hydrogen.
  • Preferred values for the one or two of R 1 to R j which is or are other than hydrogen include alkoxy such as OMe or 0Bu n , halogen such as Cl or F, hydroxy, -N(R 11 R 12 ) , -C0 2 R 11 , -CH 2 SCOR 13 , -CH 2 SR 11 , -NHCOR 11 , -0(CH 2 ) n N(R R 12 ) , -O(CH 2 ) n C0 2 R 11 , -CH 2 NHC0(CH 2 ) n C0 2 R 1 , -NHC0CH 2 0R 11 , -NHCO(CH 2 ) n OCOR 11 , -CH 2 NHCOOR 13 and CF 3 . It is also preferred for R, and R 2 , R j and R 3 , R 3 and R 4 or R 4 and R j to form, together with the carbon atoms to which they are attached, a benzene
  • R, and R 2 are independently H, nitro or halogen
  • R 3 is H, hydroxy, -0(CH 2 ) n N(R 11 R 12 ) , -OCOR 11 , -0(CH 2 ) n C0 2 R 11 , -CH 2 NHCO(CH 2 ) n C0 2 R 11 , C,-C 6 alkoxy, -NHCO(CH 2 ) n OCOR 11 , -N(R 11 R 12 ), -CH-,NHC0 2 R 13 , -CH 2 SR 11 or -NHCOR 11 ;
  • R 4 is H, halogen, C 1 -C 6 alkoxy, -CH 2 SCOR 11 , -CH 2 SR 11 or -C0 2 R 11 ; and
  • R j is H, nitro or halogen; or R 2 and R 3 , R 3 and R 4 or R 4 and R j form, together with the carbon atoms to which they are attached, an
  • R g is OMe, each of R 6 , R 7 , R, and R 10 is H; R 1 is H, nitro or halogen such as Cl; R 2 is H; R 3 is H, hydroxy, -OCOR 11 such as OAc, -NHCO(CH 2 ) n OCOR 11 such as -NHCOCH 2 OAc or -NHCOCH 2 OR 11 such as -NHCOCH 2 OH; R 4 is H and j is H or halogen such as F or Cl; or R 2 and R 3 form a benzene ring together with the carbon atoms to which they are attached.
  • R 1 is H, nitro or halogen such as Cl
  • R 2 is H
  • R 3 is H, hydroxy, -OCOR 11 such as OAc, -NHCO(CH 2 ) n OCOR 11 such as -NHCOCH 2 OAc or -NHCOCH 2 OR 11 such as -NHCOCH 2 OH
  • R 4 is H and
  • each of R,, R 6 , R 7 , R g , R-, and R 10 is H;
  • R 2 is H and
  • R 3 is -CH 2 SR 11 such as -CH 2 SMe, -CH 2 SCOR 11 such as -CH 2 SAc, -NHCO(CH 2 ) n C0 2 R 11 such as -NHCO(CH 2 ) 3 C ⁇ 2 Me, -0(CH 2 ) n C0 2 R 11 such as -0(CH 2 ) 4 C0 2 H, -0(CH 2 )N(R 11 R 12 ) such as -0(CH 2 ) 3 -NMe 2 , or -N(R 11 R 12 ) such as -NMe 2 or R 2 is -CH 2 SCOR 13 such as -CH 2 SAc or -CH 2 SR 11 such as -CH 2 SH and R 3 is H; and R 4 and R j are both H or both form, together with the carbon atoms to which they are attached
  • General formula A embraces diketopiperazines which are novel. Accordingly, the present invention provides a diketopiperazine of formula (A) as defined above, or a pharmaceutically acceptable salt or ester thereof; with the exception of compounds wherein:
  • R, to R j are defined above and are optionally protected, in the presence of a base in an organic solvent; or (ii) condensing a compound of formula (I'):
  • R 1 to R j are as defined above and are optionally protected, with a compound of formula (III) :
  • a compound of formula A produced directly by the condensation reaction between (I) and (II) or (I') and (III) may be modified, if desired, by converting one or more of groups R, to R 10 into different groups R, to R 10 .
  • These optional conversions may be carried out by methods known in themselves.
  • a compound of formula A in which one or more of R 1 to R 10 is an ester group may be converted to a compound of formula A wherein the corresponding substituent is a free -COOH group, by acid or alkaline hydrolysis at a suitable temperature, for example from ambient temperature to 100*C.
  • a compound of formula A in which one or more of R 1 to R 10 is a -C0 2 H group may be converted into a compound of formula A wherein the corresponding substituent is esterified by esterification, for example by treating the carboxylic acid with a suitable C 1 -C 6 alkyl alcohol in the presence of 1,3-dicyclohexylcarbodiimide in an inert solvent.
  • a compound of formula A in which one or more of R, to R 10 is a free -C0 2 H group may be converted into a compound of formula A in which the corresponding substituent is a group -CON(R 11 R 12 ) , wherein R 11 and R 12 are as defined above, for example by treatment with ammonia or an amine in the presence of 1,3-dicyclohexylcarbodiimide in an inert solvent.
  • a compound of formula A in which one or more of R 1 to R 10 is a free -C0 2 H group may be converted into a compound of formula A wherein the corresponding substituent is a -CH 2 OH group by reduction, for example using borane in a suitable solvent such as tetrahydrofuran.
  • a compound of formula A in which one or more of R 1 to R 10 is a nitro group may be converted into a compound of formula A in which the corresponding substituent is an amino group by reduction under standard conditions, for example by catalytic hydrogenation.
  • Protecting groups for R, to R 10 in any of the compounds of formulae (I), (I ' ) , (II) and (III) are optionally introduced prior to step (i) or step (ii) when any of groups R, to R 10 are groups which are sensitive to the condensation reaction conditions or incompatible with the condensation reaction, for example a -COOH, -CH 2 OH or amino group.
  • the protecting groups are then removed at the end of the process. Any conventional protecting group suitable for the group R, to R 10 in question may be employed, and may be introduced and subsequently removed by well-known standard methods.
  • the compounds of formula (I) may be prepared by a process comprising reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (III) as defined above, in the presence of a base in an organic solvent.
  • the compounds of formula (I') may be prepared by a process which comprises reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (II) as defined above, in the presence of a base in an organic solvent.
  • the resulting compound of formula (I) or (I') can be separated from other reaction products by chromatography.
  • the reaction of l,4-diacetyl-2,5-piperazinedione with the compound of formula (III) or (II) is suitably performed under the same conditions as described above for the condensation between compounds (I) and (II), or (I') and (III).
  • the substituted benzaldehydes of formulae (II) and (III) are known compounds or can be prepared from readily available starting materials by conventional methods.
  • the l,4-diacetyl-2,5-piperazinedione used as a starting material in the preparation of compounds of formula (I) may be prepared by treating 2,5-piperazinedione (glycine anhydride) with an acetylating agent.
  • the acetylation may be performed using any conventional acetylating agent, for example acetic anhydride under reflux or, alternatively, acetic anhydride at a temperature below reflux in the presence of 4-dimethylaminopyridine.
  • Compounds of formula (I) may alternatively be prepared directly from 2,5-piperazinedione (glycine anhydride) by a process which comprises treating the 2,5- piperazinedione with a mixture comprising a compound of formula (III) , sodium acetate and acetic anhydride at an elevated temperature, for example under reflux.
  • Compounds of formula (I') may be prepared by analogous processes, replacing compound (III) in each case by a compound of formula (II) .
  • Compounds of formula A may also be prepared by a process comprising the microwave irradiation of (i) a mixture comprising a compound of formula (I) as defined above, a compound of formula (II) and potassium fluoride on alumina, or (ii) a mixture comprising a compound of formula (I') a compound of formula (III) and potassium fluoride on alumina, or (iii) a mixture comprising l,4-diacetyl-2,5- piperazinedione, a compound of formula (II) , a compound of formula (III) and potassium fluoride on alumina.
  • Compounds of formula (A) may also be obtained directly by a process which comprises condensing together l,4-diacetyl-2,5-piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of a base in an organic solvent. Suitable bases, solvents and reaction conditions are as described above for the condensation reaction between, for example, compounds (I) and (II) .
  • An alternative direct process for the preparation of compounds of formula (A) comprises condensing together 2,5- piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of sodium acetate and acetic anhydride at elevated temperature, for example under reflux.
  • An alternative process for the preparation of compounds of formula (I) comprises treating a compound of formula (V) :
  • R 6 to R 10 are as defined above, X is a halogen and R' is a C 1 -C 6 alkyl group, with ammonia followed by acetic anhydride.
  • Compounds of formula (I') may be prepared by an analogous process which comprises treating a compound of formula (V )
  • R 1 to R j , X and R 1 are as defined above, with ammonia followed by acetic anhydride.
  • X in formula (V) or (V) is typically iodine.
  • R 1 is, for example, a C,-C 4 alkyl group such as a methyl, ethyl, propyl, i-propyl, butyl, sec-butyl or tert-butyl group.
  • Suitable salts include salts with pharmaceutically acceptable, inorganic or organic, bases.
  • inorganic bases include ammonia and carbonates, hydroxides and hydrogen carbonates of group I and group II metals such as sodium, potassium, magnesium and calcium.
  • organic bases include aliphatic and aromatic amines such as methylamine, triethylamine, benzylamine, dibenzylamine or ⁇ - or ⁇ -phenylethylamine, and heterocyclic bases such as piperidine, 1-methylpiperidine and morpholine.
  • esters include branched or unbranched, saturated or unsaturated C 1 -C 6 alkyl esters, for example methyl, ethyl and vinyl esters.
  • Preferred compounds of formula A are depicted by means of their subsitution patterns in Table 1 which follows. The compound numbering is adhered to in the rest of the specification. Characterising data for the compounds are set out in Table 2 in Examole 16. TABLE 1
  • the diketopiperazines of formula (A) both novel and known and their pharmaceutically acceptable salts and esters (referred to hereinafter as the "present compounds") have utility as inhibitors of PAI. Elevated levels of PAI- 1, by reducing the net endogenous fibrinolytic capacity, can contribute to the pathogenesis of various thrombotic disorders including myocardial infarction, deep vein thrombosis and disseminated intravascular coagulation. The present compounds therefore can act as inhibitors of the tPA/PAI-1 interaction. The present compounds can be used in the treatment of haemostatic disorders.
  • a human or animal e.g.
  • a mammal can therefore be treated by a method comprising administration of a therapeutically effective amount of a diketopiperazine of formula (A) or a pharmaceutically or veterinarily acceptable salt thereof.
  • Tissue plasminogen activator (tPA) is used as a fibrinolytic agent in the treatment of thrombotic disorders. The efficacy of the tPA in this role may be enhanced if it is administered together with a PAI inhibitor.
  • a human or animal e.g. a mammal, can therefore be treated by a method comprising the combined administration of a therapeutically effective amount of tPA and a therapeutically effective amount of any one of the present compounds.
  • the present invention also provides products containing a diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof and tPA as a combined preparation for simultaneous, separate or sequential use in the treatment of thrombotic disorders, for example where there is inappropriate PAI activity.
  • the present compound is formulated for oral or parenteral (intravenous, intramuscular or subcutaneous) administration and the tPA is formulated for intravenous administration.
  • one of the present compounds may be administered to a patient together with tPA to enhance the efficacy of the tPA treatment.
  • early re-occlusion following treatment of a patient with tPA may be prevented by the post-MI administration of one of the present compounds.
  • the compounds of formula (A) have been tested in a PAI functional assay. In this assay, a compound is incubated with PAI-1 prior to addition to the tPA assay system. Inhibition of PAI-1 results in the production of plasmin from plasminogen.
  • plasmin cleaves the chromogenic substrate S2251 (Kabi Vitrum) producing pNA (p- nitroaniline) which is detected spectrophoto etrically at 405 nm (K.Nilsson et al, Fibrinolysis (1987) l , 163-168).
  • the results of the assay are reported in Example 1 which follows.
  • the present compounds can be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions or parenterally, for example intramuscularly, intravenously or subcutaneously.
  • the present compounds may therefore be given by injection or infusion.
  • the dosage depends on a variety of factors including the age, weight and condition of the patient and the route of administration. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered alone to adult humans is 0.001 to 10 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration.
  • the dosage adopted for each route of administration is typically from 0.001 to 10 mg, more typically 0.01 to 5 mg per kg body weight for a compound of the invention and from 5 to 500mg administered intravenously for the tPA.
  • a suitable dosage regimen for the tPA is 100 mg given intravenously over 3 hours as follows: 10% of the total dose as an i.v. bolus over 1-2 minutes, 50% of the total dose as an infusion over 1 hour, 40% of the total dose as an infusion over the subsequent 2 hours.
  • a diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof is formulated for use as a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent.
  • the compositions are typically prepared following conventional methods and are administered in a pharmaceutically or veterinarily suitable form.
  • An agent for use as an inhibitor of PAI comprising any one of the present compounds is therefore provided.
  • the solid oral forms may contain, together with the active compound, diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose, or polyvinyl pyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs, sweeteners; wetting agents such as lecithin, polysorbates, lauryl sulphates.
  • diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch
  • lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols
  • Such preparations may be manufactured in known manners, for example by means of mixing, granulating, tabletting, sugar coating, or film-coating processes.
  • Liquid dispersions for oral administration may be syrups, emulsions and suspensions.
  • the syrups may contain as carrier, for example, saccharose or saccharose with glycerol and/or annitol and/or sorbitol.
  • a syrup for diabetic patients can contain as carriers only products, for example sorbitol, which do not metabolise to glucose or which only metabolise a very small amount to glucose.
  • the suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol.
  • Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.
  • sterile water olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride.
  • Some of the present compounds are insoluble in water.
  • a compound may be encapsulated within liposomes.
  • EXAMPLE 2 I PHARMACEUTICAL COMPOSITION Tablets, each weighing 0.15 g and containing 25 mg of a compound of the invention can be manufactured as follows: Composition for 10.000 tablets compound of the invention (250 g) lactose (800 g) corn starch (415 g) talc powder (30 g) magnesium stearate (5 g)
  • the compound of the invention, lactose and half of the corn starch are mixed. The mixture is then forced through a sieve 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) . The resulting paste is used to granulate the powder. The granulate is dried and broken up into small fragments on a sieve of 1.4 mm mesh size. The remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.
  • Compound 16 is treated with ammonia and subsequently with acetic anhydride to yield l-acetyl-3- benzylidenepiperazine-2,5-dione (18) .
  • Example 5 Preparation of compound 96 l-Acetyl-3-benzylidene-2,5-piperazinedione (one equivalent), prepared according to Reference Example 1, wa ⁇ treated with 5-(4-formylphenoxy)pentanoic acid, methyl ester in the presence of Cs 2 C0 3 (1-1.1 equivalents) in DMF at 80-100 * C for 1-8 hours. The title compound was obtained in 39% yield.
  • Example 6 Preparation of Compound 31 l-Acetyl-3-benzylidene-2,5-piperazinedione (one equivalent) , prepared according to Reference Example 1, was treated with 3-acetoxybenzaldehyde (one equivalent) in the presence of triethylamine (1-2 equivalents) in DMF at 130*C for 2-6 hours. The title compound was obtained in 61% yield.
  • 3- acetoxybenzaldehyde by the appropriately substituted benzaldehyde, the following compounds were prepared:
  • Example 7 Preparation of compound 103 l-Acetyl-3-(4-methoxybenzylidene)-2,5-piperazinedione (1 equivalent) , which is compound (9) mentioned in Example 3, was treated with 2-fluorobenzaldehyde (1 equivalent) in the presence of Cs 2 C0 3 (1-1.1 equivalents) in DMF at 80- 100°C for 1-6 hours. The title compound was obtained in 69% yield.
  • Example 8 Preparation of compound 28 l-Acetyl-3-(4-methoxybenzylidene)-2,5-piperazinedione (1 equivalent), compound (9) in Example 3, was treated with 2-nitrobenzaldehyde (1 equivalent) in triethylamine (1-2 equivalents) and DMF at 130 " C for 2-6 hours. The title compound was obtained in 45% yield. Characterising data are set out in Example 16.
  • Example 9 Preparation of Compound 77 l-Acetyl-3-(4-acetamidobenzylidene)-2,5- piperazinedione (1 equivalent) , prepared according to Reference Example 2, was treated with 2,4- difluorobenzaldehyde (1 equivalent) in the presence of Cs 2 C0 3 (1-1.1 equivalents) in DMF at 80-100"C for 1-6 hours. The title compound was obtained in 60% yield. By the same method, but replacing 2,4- difluorobenzaldehyde by the appropriately substituted benzaldehyde, the following compounds were obtained:
  • Example 10 Preparation of compound 22 l,4-Diacetyl-2,5-piperazinedione (1 equivalent), prepared by the published procedure mentioned in Example 3, was treated with benzaldehyde (2.1 equivalents) in the presence of triethylamine (2.5 equivalents) in DMF at 130 ⁇ C for 8 hours. The title compound was obtained in 89% yield. Characterising data are set out in Example 16.
  • Example 11 Preparation of compound 35 l,4-Diacetyl-2,5-piperazinedione (1 equivalent), prepared by the published procedure mentioned in Example 3, was treated with 3-nitrobenzaldehyde (1 equivalent) in the presence of triethylamine (1 equivalent) in DMF at room temperature for 18-20 hrs. The title compound was obtained in 9% yield together with l-acetyl-3-(3-nitrobenzylidene)- 2,5-piperazinedione (66% yield). Characterising data are set out in Example 16.
  • Example 12 Preparation of Compound 86 l-Acetyl-3-(4-dimethylaminobenzylidene)-2,5- piperazinedione (1 equivalent) as described in Reference Example 3 was treated with 4-acetamidobenzaldehyde (1 equivalent) in the presence of Cs 2 C0 3 (1 equivalent) in DMF at 80*C for 2-6 hours. The title compound was obtained in 56% yield. Characterising data are set out in Example 16.
  • Compound 98 the hydrochloride salt of compound 102, was prepared by treatment of a solution of compound 102 in THF with 2 molar hydrochloric acid followed by sonication until a clear solution was obtained. The solvent was then removed in vacuo and the residual solution was freeze-dried to give compound 98.
  • Compound 99 was prepared by bubbling HCl gas through a solution of the corresponding free base in THF, followed by evaporation to dryness.

Abstract

PCT No. PCT/GB93/01734 Sec. 371 Date Apr. 11, 1995 Sec. 102(e) Date Apr. 11, 1995 PCT Filed Aug. 16, 1993 PCT Pub. No. WO94/04512 PCT Pub. Date Mar. 3, 1994Diketopiperazines of the formula: <IMAGE>ame or different, is independently selected from the group consisting of hydrogen, C1-C6 alkyl unsubstituted or substituted by one or more halogen atoms, C1-C6 alkoxy, C1-C6 alkylthio, halogen, hydroxy, nitro, phenyl, -cyano, -CH2OH, -CH2COOH, -CO2R11, -NHCOR11, -NHSO2R13, -SO2R13, -CON(R11R12), -SOR13, -SO2N(R11R12), -N(R11R12), and -O(CH2)nN(R11R12), -O(CH2)nCO2R11, -OCOR11, -CH2OCOR11, -CH2NHCOR11, -CH2NHCOOR13, -CH2SR11, -CH2SCOR11, -CH2S(O)mR13 wherein m is 1 or 2, -CH2NHCO(CH2)nCO2R11, -N(R11)COR12, -NHCOCF3, -NHCO(CH2)nCO2R11, -NHCO(CH2)nOCOR11 and -NHCO(CH2)nOR11 wherein n is 0 or is an integer of from 1 to 6, each of R11 and R12 is independently H or C1-C6 alkyl and R13 is C1-C6 alkyl; or any of R1 and R2, R2 and R3, R3 and R4 and R4 and R5, or R6 and R7, R7 and R8, R8 and R9 and R9 and R10, form together with the carbon atoms to which they are attached a benzene ring; and pharmaceutically acceptable salts and esters thereof are inhibitors of the plasminogen activator inhibitor.

Description

Pharmaceutically active d1ketop1periz1nes The present invention relates to compounds useful as inhibitors of plasminogen activator inhibitor (PAI) , to their preparation and to pharmaceutical and veterinary compositions containing them.
Plasminogen activators (PAs) are serine proteases which control the activation of the zymogen, plasminogen, to the active enzyme plasmin. Plas in is important in a number of physiological and pathological processes including fibrinolysis, tissue remodelling, tumour growth and metastasis. The glycoprotein plasminogen activator inhibitor (PAI) is an endogenous fast-acting inhibitor of PA activity. PAI is a member of the serpin family and is synthesised by a variety of cells including endothelial cells. An imbalance between PAs and PAI contributes to a number of pathological conditions including haemostasis, inflammation, tumour growth and metastasis.
The present invention provides the use of a diketopiperazine of formula (A) :
wherein each of R., to R10, which may be the same or different, is independently selected from hydrogen, C,-C6 alkyl unsubstituted or substituted by one or more halogen atoms, C1-C6 alkoxy, C1-C6 alkylthio, halogen, hydroxy, nitro, optionally substituted phenyl, cyano, -CH2OH, -CH2COOH, -C02R11, -NHCOR11, -NHS02R13, -S02R13, -C0N(R11R12) , -SOR13, -S02N(R11R12) , -N(R11R12), -0 (CH2) nN (R11R12) , -0(CH2)nC02R11, -0C0R11, -CH2NHC0R11, -CH2NHC00R13, -CH2SR11, -CH2SC0R11, -CH-.S (O) mR13 wherein is 1 or 2 ,
-CH2NHC0(CH2) -N (R11) COR12, -NHC0CF3, -NHCO (CH2) nC02R1\ -NHC0(CH2)n0C0R11 and -NHCO(CH2)nOR11 wherein n is 0 or is an integer of from 1 to 6, each of R11 and R12 is independently H or C^-C6 alkyl and R13 is C1-C6 alkyl; or any of R. and R2, R2 and R3, R3 and R4 and R4 and Rj, or R6 and R7, R7 and Rg, Rg and R, and R^, and R10, form together with the carbon atoms to which they are attached a benzene ring which is optionally substituted; or a pharmaceutically acceptable salt or ester thereof; in the manufacture of a medicament for use as an inhibitor of plasminogen activator inhibitor. The numerals 1 to 10 denote ring positions on the phenyl groups in formula A. The letters a and b refer to the two phenyl rings themselves.
When any two adjacent groups of R1 to R10 form, together with the carbon atoms to which they are attached, a benzene ring, that ring is either unsubstituted or it may be substituted by any of the options specified above for R1 to R10. The benzene ring forms, together with ring a. or b respectively, an optionally substituted naphthalene ring structure. When ring a or b is substituted phenyl, the benzene ring may be substituted at any of the ortho, meta and para positions by one or more substituents, for example one, two or three substituents, which may be the same or different, independently selected from the groups specified above for R1 to R10 other than hydrogen.
A C1-C6 alkyl group is typically a C^C^ alkyl group, for example a methyl, ethyl, propyl, i-propyl, n-butyl, sec-butyl or tert-butyl group. A halogen is, for example, fluorine, chlorine, bromine or iodine. A C1-C6 alkyl group substituted by halogen may be substituted by 1, 2 or 3 halogen atoms. It may be a perhaloalkyl group, for example trifluoromethyl.
A C1-C6 alkoxy group is typically a C^C^ alkoxy group, for example a methoxy, ethoxy, propoxy, i-propoxy, n-butoxy, sec-butoxy or tert-butoxy group. A C1-C6 alkylthio group is typically a C.-C^ alkylthio group, for example methylthio, ethylthio, propylthio, i-propylthio, n- butylthio, sec-butylthio or tert-butylthio.
In compounds of formula A free rotation may occur at room temperature about the single bonds connecting rings a and b to the double bonds at positions 3 and 6 of the piperazine-2,5-dione ring. Positions 2 and 6, and positions 3 and 5, in both rings a and b can therefore be considered as equivalent. As a consequence the following pairs of substituents can be viewed as interchangeable: R1 and Rj; R2 and R4; R6 and R10; and R7 and R,.
Preferably one of rings a and b is unsubstituted or is mono-substituted whilst the other ring is unsubstituted or is substituted at one or more of positions 2 to 6. The ring which is mono-substituted may carry the substituent at any one of positions 2 to 6, for instance position 3 or 4, especially position 4. Thus for instance, when ring b is mono-substituted, one of R6 to R10 is other than hydrogen, preferably R7 or Rg, especially Rg. When ring a is mono- substituted, one of R, to j is other than hydrogen, preferably R2 or R3, especially R3. When one of rings a and b is mono-substituted the substituent R, to Rj, or R6 to R10 respectively, is preferably selected from a halogen, for instance fluorine; an alkoxy group, for instance OMe; and an acetamido group -NHAc in which Ac denotes acetyl. When one of rings a and b is unsubstituted, or is mono-substituted as described in the above paragraph, the other ring may bear any desired substitution pattern. For instance, the other ring may be unsubstituted or may be mono-, di- or tri-substituted at any of positions 2 to 6. The said other ring may, for instance, be mono- substituted at any of positions 2 to 6. It may also be 2,3-, 2,4-, 2,5-, 2,6-, 3,4- or 3,5- disubstituted, or 2,3,4-, 2,3,5-, 2,3,6- or 3,4,5-trisubstituted. Thus, when the said other ring is a and is mono-substituted, four of R1 to Rj are hydrogen and one is other than hydrogen. When the said other ring is ring a and is disubstituted, three - A - of R- to Rj are hydrogen and two are other than hydrogen. For example R, and R2, or R1 and R3, or R1 and R , or R, and Rj, or R2 and R3, or R2 and R4 are other than hydrogen whilst, in each case, the other three of R, to Rj are hydrogen.
When the said other ring is ring a and is trisubstituted, two of R1 to Rj are hydrogen and three are other than hydrogen. For example, R,, R2 and R3, or R,, R2 and R4, or R^ R2 and Rj, or R2, R3 and R4 are other than hydrogen whilst, in each case, the other two of R, to Rj are hydrogen.
When the said ring is b and is mono-substituted, four of R6 to R10 are hydrogen and one is other than hydrogen. When the said other ring is b and is di-substituted, three of R6 to R10 are hydrogen and two are other than hydrogen. For example R6 and R7, or R6 and Rg, or R6 and R,, or R6 and R10, or R7 and Rg, or R7 and R,, are other than hydrogen whilst, in each case, the other three of R6 to R10 are hydrogen. When the said other ring is b and is trisubstituted, two of R6 to R10 are hydrogen and three are other than hydrogen. For example R6, R7 and Rg, or R6, R7 and R^,, or R6, R7 and R10, or R7, Rg and R-, are other than hydrogen whilst, in each case, the other two of R6 to R10 are hydrogen. Alternatively, any two adjacent substituents in the said other ring may, together with the carbon atoms to which they are attached, complete a second benzene ring which is optionally substituted, thus forming an optionally substituted naphthyl group with the said other ring. For instance, in ring a R1 and R2, or R2 and R3 may form together with carbon atoms 2 and 3, or 3 and 4 respectively, an optionally substituted benzene ring which, in turn, forms with ring a a naphthyl group which iε unsubstituted or substituted by one or more groups specified above for R1 to R10. In ring b R6 and R7, or R7 and Rg may form, together with carbon atoms 2 and 3 or 3 and 4 respectively, an optionally substituted benzene ring which, in turn, forms with ring b a naphthyl group which is unsubstituted or substituted by one or more groups specified above for R, to R10. Typically the naphthyl group in either case is unsubstituted or is monosubstituted at position 1,2,3 or 4 of the naphthalene ring structure, especially position 4. For example R, and R2 together with ring a, or R6 and R7 with ring b_, form a 4-dimethylamino-l- naphthyl group. In a preferred series of compounds of formula A each of R6 to R10 is hydrogen. In another preferred series of compounds, one of R6 to R10 is selected from alkoxy, NHCOR1 and halogen and the other four of R6 to R10 are H. Alkoxy may be, for instance, OMe or 0Bun. NHCOR11 is typically - NHAc. Halogen is typically F or Cl. Preferably Rg is alkoxy, especially OMe or 0Bun; NHCOR11, especially -NHAc; or halogen, especially F or Cl; and each of R6, R7, , and R10 is H.
In the above-mentioned series of preferred compounds R, to Rj are all hydrogen, or one or two of R1 to Rj are other than hydrogen whilst the others are hydrogen. For instance one of R1f R2 and R3 is other than hydrogen. Alternatively R1 and R3, or R2 and R3, are other than hydrogen. Preferred values for the one or two of R1 to Rj which is or are other than hydrogen include alkoxy such as OMe or 0Bun, halogen such as Cl or F, hydroxy, -N(R11R12) , -C02R11, -CH2SCOR13, -CH2SR11, -NHCOR11, -0(CH2)nN(R R12) , -O(CH2)nC02R11, -CH2NHC0(CH2)nC02R 1, -NHC0CH20R11, -NHCO(CH2)nOCOR11, -CH2NHCOOR13 and CF3. It is also preferred for R, and R2, Rj and R3, R3 and R4 or R4 and Rj to form, together with the carbon atoms to which they are attached, a benzene ring.
Particularly preferred compounds are those wherein R6, R7, Ε-~ and R10 are each H, Rg is selected from H, OMe and -NHAc and each of R1 to Rj is as specified above. In these preferred compounds R1 to R5 are preferably each independently selected from H, halogen, hydroxy, C^-C6 alkoxy, nitro, -CH2SCOR11, -CH2SR11, -OCOR13, CF3, -0(CH2)nN(R11R12) , -0(CH2)nC02R11, -CH2NHCO(CH2)nC02R11 , -NHCO(CH2)nOR11, -N(R11R12), -NHCO(CH2)nOCOR11, -NHCO(CH2)nC02R11 and -CHjNHCOjR13 or R, and R2, R2 and R3, R3 and R4, or R4 and Rj, form with the carbon atoms to which they are attached an optionally substituted benzene ring. Still more preferably, R, and R2 are independently H, nitro or halogen, R3 is H, hydroxy, -0(CH2)nN(R11R12) , -OCOR11, -0(CH2)nC02R11, -CH2NHCO(CH2)nC02R11, C,-C6 alkoxy, -NHCO(CH2)nOCOR11, -N(R11R12), -CH-,NHC02R13, -CH2SR11 or -NHCOR11; R4 is H, halogen, C1-C6 alkoxy, -CH2SCOR11, -CH2SR11 or -C02R11; and Rj is H, nitro or halogen; or R2 and R3, R3 and R4 or R4 and Rj form, together with the carbon atoms to which they are attached, an optionally substituted benzene ring.
In one embodiment Rg is NHAc, each of R6, R7, R^, and R10 is H; R, is H or halogen such as Cl or F; R2 is H, R3 is halogen such as F or Cl, C1-C6 alkoxy such as OMe, -N(R11R12) such as NMe2 or -NHCOOR13 such as -NHCOOBu*; R4 is H and Rj is halogen such as F, Cl, Br, or is CF3.
In a second embodiment Rg is OMe, each of R6, R7, R, and R10 is H; R1 is H, nitro or halogen such as Cl; R2 is H; R3 is H, hydroxy, -OCOR11 such as OAc, -NHCO(CH2)nOCOR11 such as -NHCOCH2OAc or -NHCOCH2OR11 such as -NHCOCH2OH; R4 is H and j is H or halogen such as F or Cl; or R2 and R3 form a benzene ring together with the carbon atoms to which they are attached.
In a third embodiment each of R,, R6, R7, Rg, R-, and R10 is H; R2 is H and R3 is -CH2SR11 such as -CH2SMe, -CH2SCOR11 such as -CH2SAc, -NHCO(CH2)nC02R11 such as -NHCO(CH2)3Cθ2Me, -0(CH2)nC02R11 such as -0(CH2)4C02H, -0(CH2)N(R11R12) such as -0(CH2)3-NMe2, or -N(R11R12) such as -NMe2 or R2 is -CH2SCOR13 such as -CH2SAc or -CH2SR11 such as -CH2SH and R3 is H; and R4 and Rj are both H or both form, together with the carbon atoms to which they are attached, a benzene ring.
In one embodiment of the invention the compound of formula A is the following compound 3:
D
Certain diketopiperazines have been disclosed as having utility as bioactive agents. Yokoi et al in J. Antibiotics vol XLI No. 4, pp 494-501 (1988) describe structure-cytotoxicity relationship studies on a series of diketopiperazines related to neihumicin, a compound obtained from the micro-organism Micromonospora neihuensis. Kamei et al in J. Antibiotics vol XLIII No. 8, 1018-1020 disclose that two diketopiperazines, designated piperafizines A and B, have utility as potentiators of the cytotoxicity of vincristine.
General formula A embraces diketopiperazines which are novel. Accordingly, the present invention provides a diketopiperazine of formula (A) as defined above, or a pharmaceutically acceptable salt or ester thereof; with the exception of compounds wherein:
(i) each of R1 to R10 is H; (ii) R, and R6 are both Cl and the rest of R2 to R10 are H; R2 and R7 are both Cl and the rest of R1 to R10 are H; R3 and Rg are both Me and the rest of R, to R10 are H; R2, Rj, R7 and R10 are all Me and the rest of R1 to R10 are H; R2, R3, R4, R7, Rg and R9 are all OMe and R,, Rj, R6 and R10 are H; (iϋ) R8 is OMe and the rest of R1 to R10 are H; and (iv) 3-p-nitrobenzylidene-6-benzylidene-2,5- piperazinedione and 3,6-di-p-nitrobenzylidene-2,5- piperazinedione.
Examples of specific compounds of formula A are as follows. The compound numbering is adhered to in the rest of the specification: (3Z,6Z,)-6-benylidene-3-(4-methoxybenzylidene)-2,5- piperazinedione (compound 3)
(3Z,6Z)-6-Benzylidene-3-(2,6-dichlorobenzylidene)-2,5- piperazinedione (compound 21) (3Z,6Z)-3-(4-Acetoxybenzylidene)-6-benzylidene-2,5- piperazinedione (compound 23)
(3Z,6Z)-6-Benzylidene-3-(4-nitrobenzylidene)-2,5- piperazinedione (compound 74)
3,6-Dibenzylidene-2,5-piperazinedione (compound 22) (mixture of isomers)
(3Z,6Z)-6-Benzylidene-3-(3-nitrobenzylidene)-2,5- piperazinedione (compound 24)
(3Z,6Z)-6-Benzylidene-3-(2-nitrobenzylidene)-2,5- piperazinedione (compound 65) (3Z,6Z)-6-Benzylidene-3-(4-ethoxybenzylidene)-2,5- piperazinedione (compound 25)
(3Z,6Z)-6-Benzylidene-3-(4-cyanobenzylidene)-2,5- piperazinedione (compound 105)
(3Z,6Z)-3-(4-Aminobenzylidene)-6-benzy1idene-2,5- piperazinedione (compound 30)
(3Z,6Z)-3-(3-Acetoxybenzylidene)-6-benzylidene-2,5- piperazinedione (compound 31)
(3Z,6Z)-3-(2-Acetoxybenzylidene)-6-benzylidene-2,5- piperazinedione (compound 32) (3Z ,6Z)-6-Benzylidene-3-(3-hydroxybenzylidene)-2 ,5- piperazinedione (compound 33)
(3Z ,6Z)-3-(4-Acetamidobenzylidene)-6-benzy1idene-2 ,5- piperazinedione (compound 34)
(3Z,6Z)-3-(2-Acetamidobenzylidene)-6-benzylidene-2,5- piperazinedione (compound 38)
(3Z,6Z)-3-(2-Aminobenzylidene)-6-benzylidene-2,5- piperazinedione (compound 39)
(3Z,6Z)-3-(4-Acetoxymethylbenzylidene)-6-benzylidene-2,5- piperazinedione (compound 43) (3Z,6Z)-3-(4-Acetamidomethylbenzylidene)-6-benzylidene-2,5- piperazinedione (compound 44) (3Z,6Z)-3,6-Dibenzylidene-2,5-piperazinedione (compound 45)
(3Z,6Z)-6-Benzylidene-3-(4-butoxybenzylidene)-2,5- piperazinedione (compound 48)
(3Z,6Z)-6-Benzylidene-3-(4-tert-butylbenzylidene)-2,5- piperazinedione (compound 51)
(3Z,6Z)-6-Benzylidene-3-(4-isopropoxybenzylidene)-2,5- piperazinedione (compound 52)
(3Z,6Z)-6-Benzylidene-3-(2,4-difluorobenzylidene)-2 ,5- piperazinedione (compound 54) (3Z,6Z)-6-Benzylidene-3-(2-bromobenzylidene)-2,5- piperazinedione (compound 55)
(3Z,6Z)-6-Benzylidene-3-(4-methylthiomethylbenzylidene)-
2,5-piperazinedione (compound 59)
(3Z,6Z)-6-Benzylidene-3-(3-thioacetoxymethylbenzylidene)- 2,5-piperazinedione (compound 61)
3-((3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene)methylbenzoic acid, methyl ester (compound 62)
(3Z,6Z)-6-Benzylidene-3-(3-mercaptomethylbenzylidene)-2,5- piperazinedione (compound 64) (3Z,6Z)-6-Benzylidene-3-(4-tert- butoxycarbonylaminobenzylidene)-2,5-piperazinedione
(compound 66)
(3Z,6Z)-6-Benzylidene-3-(4-(3-N,N-dimethylaminopropoxy) benzylidene)-2,5-piperazinedione (compound 75) (3Z,6Z)-6-Benzylidene-3-(4-thioacetoxymethylbenzylidene)-
2,5-piperazinedione (compound 76)
(3Z,6Z)-6-Benzylidene-3-(2-chloro-4-hydroxybenzylidene)-
2,5-piperazinedione (compound 85)
(3Z,6Z)-6-Benzylidene-3-(3,4-dimethoxybenzylidene)-2,5- piperazinedione (compound 90)
4-[ (3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidenej ethylphenoxyacetic acid, methyl ester (compound
93)
4-(4-[ (3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene]methylbenzylcarbamoyl) butanoic acid, methyl ester (compound 94) 4-(4-((3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene)methylbenzylcarbamoyl)pentanoic acid, methyl ester
(compound 95)
5-[4-((3Z ,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene)methylphenoxy]pentanoic acid, methyl ester
(compound 96)
5-[4-((3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene)methylphenoxy]pentanoic acid (compound 97)
(3Z,6Z)-6-Benzylidene-3-(4-(2-N,N- dimethylaminoethoxy)benzylidene)-2 ,5-piperazinedione, hydrochloride (compound 99)
(3Z,6Z)-6-Benzylidene-3-(4-(2-N,N- dimethylaminoethoxy)benzylidene)-2,5-piperazinedione
(compound 102) 4-[ (3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene]methylphenoxyacetic acid (compound 101)
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 26)
(3Z,6Z)-6-(4-Methoxybenzylidene)-3-(2-nitrobenzylidene)- 2,5-piperazinedione (compound 28)
(3Z,6Z)-3-(2,6-Dichlorobenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 29)
(3Z,6Z)-3-(4-Hydroxybenzylidene)-6-(4-methoxybenzylidene)-
2,5-piperazinedione (compound 36) (3Z,6Z)-3-(4-Acetoxybenzylidene)-6-(4-methoxybenzylidene)-
2,5-piperazinedione (compound 37)
(3Z ,6Z)-3-(4-Methoxybenzylidene)-6-(4-N- methylacetamidobenzylidene)-2,5-piperazinedione (compound
41) (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4- methylsulfonylbenzylidene)-2,5-piperazinedione (compound
46)
(3Z,6Z)-3-(4-Butoxybenzylidene)-6-(4-methoxybenzylidene)-
2,5-piperazinedione (compound 47) (3Z,6Z)-3-(4-;Lsopropoxybenzylidene)-6-(4- ethoxybenzylidene)-2,5-piperazinedione (compound 49) (3Z,6Z)-3-(4-methoxybenzylidene)-6-(4-tert- butylbenzylidene)-2,5-piperazinedione (compound 50) (3Z,6Z)-3-(2-Bromobenzylidene)-6-(4-methoxybenzylidene)- 2,5-piperazinedione (compound 53) (3Z,6Z)-(4-Methoxybenzylidene)-6-(4-tert- butoxycarbonylaminomethylbenzylidene)-2,5-piperazinedione (compound 56)
(3Z ,6Z)-3-(4-Methoxybenzylidene)-6-(4- methylthiomethylbenzylidene)-2,5-piperazinedione (compound 57)
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4- methylsulfonylmethylbenzylidene)-2,5-piperazinedione (compound 60)
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(3- thioacetoxymethylbenzylidene)-2,5-piperazinedione (compound 63)
(3Z,6Z)-3-(4-Aminomethylbenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 67) (3Z,6Z)-3-(2,4-Difluorobenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 69) (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(2- trifluoromethylbenzylidene)-2,5-piperazinedione (compound 70)
(3Z ,6Z)-3-(2 ,4-Dimethoxybenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 73)
4-[ (3Z,6Z)-6-(4-Methoxybenzylidene)-2,5-dioxopiperazin-3- ylidene] methylbenzamide (compound 80) (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4- trimethylacetoxybenzylidene)-2,5-piperazinedione (compound 81)
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4- methoxycarbonylaminobenzylidene)-2,5-piperazinedione (compound 83)
(3Z,6Z)-3-(2-Chloro-4-hydroxybenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 84) (3Z,6Z)-3-(4-Acetoxyacetylaminobenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 87)
(3Z,6Z)-3-(3,4-Dimethoxybenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 91) 4-( (3Z,6Z)-6-(4-Methoxybenzylidene)-2,5-dioxopiperazin-3- ylidene)-4-methylbenzylcarbamoyl)butanoic acid, methyl ester (compound 100)
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(2-naphthylmethylene)-
2,5-piperazinedione (compound 27)
(3Z,6Z)-3-(4-Hydroxyacetylaminobenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione (compound 88)
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-benzylidene-2,5- piperazinedione (compound 34)
(3Z,6Z)-3,6-Di-(3-Nitrobenzylidene)-2,5-piperazinedione
(compound 35) (3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(2,6- dichlorobenzylidene)-2,5-piperazinedione (compound 40)
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-chlorobenzylidene)-
2,5-piperazinedione (compound 42)
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4- acetoxymethylbenzylidene)-2,5-piperazinedione (compound 58)
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(2-fluorobenzylidene)-
2,5-piperazinedione (compound 71)
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-fluorobenzylidene)-
2,5-piperazinedione (compound 72) (3Z,6Z)-6-(Benzylidene)-3-(2,4-difluorobenzylidene)-2,5- piperazinedione (compound 76)
(3Z,6Z)-6-(4-Acetamidobenzylidene)-3-(2- trifluoromethylbenzylidene)-2,5-piperazinedione (compound
78) (3Z,6Z)-6-(4-Acetamidobenzylidene)-3-(2-bromobenzylidene)-
2,5-piperazinedione (compound 79)
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4- trimethylacetoxybenzylidene)-2,5-piperazinedione (compound
82) (3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4- dimethylaminobenzylidene)-2,5-piperazinedione (compound 86) (3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-tert- butoxycarbonylaminomethylbenzylidene)-2,5-piperazinedione (compound 68)
Compounds of formula A, both known and novel, may be prepared by a process which comprises either (i) condensing compound of formula (I)
wherein R6 to R10 are as defined above and are optionally protected, with a compound of formula (II) :
wherein R, to Rj are defined above and are optionally protected, in the presence of a base in an organic solvent; or (ii) condensing a compound of formula (I'):
wherein R1 to Rj are as defined above and are optionally protected, with a compound of formula (III) :
wherein R6 to R10 are as defined above and are optionally protected, in the presence of a base in an organic solvent; and, in either case (i) or (ii) , if required, removing optionally present protecting groups and/or, if desired, converting one compound of formula A into another compound of formula A, and/or, if desired, converting a compound of formula A into a pharmaceutically acceptable salt or ester thereof, and/or, if desired, converting a salt or ester into a free compound, and/or, if desired, separating a mixture of isomers of compounds of formula A into the single isomers. A compound of formula A produced directly by the condensation reaction between (I) and (II) or (I') and (III) may be modified, if desired, by converting one or more of groups R, to R10 into different groups R, to R10. These optional conversions may be carried out by methods known in themselves. For example, a compound of formula A in which one or more of R1 to R10 is an ester group may be converted to a compound of formula A wherein the corresponding substituent is a free -COOH group, by acid or alkaline hydrolysis at a suitable temperature, for example from ambient temperature to 100*C.
A compound of formula A in which one or more of R1 to R10 is a -C02H group may be converted into a compound of formula A wherein the corresponding substituent is esterified by esterification, for example by treating the carboxylic acid with a suitable C1-C6 alkyl alcohol in the presence of 1,3-dicyclohexylcarbodiimide in an inert solvent.
A compound of formula A in which one or more of R, to R10 is a free -C02H group may be converted into a compound of formula A in which the corresponding substituent is a group -CON(R11R12) , wherein R11 and R12 are as defined above, for example by treatment with ammonia or an amine in the presence of 1,3-dicyclohexylcarbodiimide in an inert solvent. A compound of formula A in which one or more of R1 to R10 is a free -C02H group may be converted into a compound of formula A wherein the corresponding substituent is a -CH2OH group by reduction, for example using borane in a suitable solvent such as tetrahydrofuran.
A compound of formula A in which one or more of R1 to R10 is a nitro group may be converted into a compound of formula A in which the corresponding substituent is an amino group by reduction under standard conditions, for example by catalytic hydrogenation.
Protecting groups for R, to R10 in any of the compounds of formulae (I), (I ' ) , (II) and (III) are optionally introduced prior to step (i) or step (ii) when any of groups R, to R10 are groups which are sensitive to the condensation reaction conditions or incompatible with the condensation reaction, for example a -COOH, -CH2OH or amino group. The protecting groups are then removed at the end of the process. Any conventional protecting group suitable for the group R, to R10 in question may be employed, and may be introduced and subsequently removed by well-known standard methods. The condensation reaction between compounds (I) and (II) or (I') and (III) is suitably performed in the presence of a base which is potassium t-butoxide, sodium hydride, potassium carbonate, sodium carbonate, caesium carbonate, sodium acetate, potassium fluoride on alumina, or triethylamine in a solvent such as dimethylformamide, or in the presence of potassium t-butoxide in t-butanol or a mixture of t-butanol and dimethylformamide. The reaction is typically performed at a temperature from 0°C to the reflux temperature of the solvent. The compounds of formula (I) may be prepared by a process comprising reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (III) as defined above, in the presence of a base in an organic solvent. Similarly, the compounds of formula (I') may be prepared by a process which comprises reacting l,4-diacetyl-2,5- piperazinedione with a compound of formula (II) as defined above, in the presence of a base in an organic solvent.
If necessary, the resulting compound of formula (I) or (I') can be separated from other reaction products by chromatography. The reaction of l,4-diacetyl-2,5-piperazinedione with the compound of formula (III) or (II) is suitably performed under the same conditions as described above for the condensation between compounds (I) and (II), or (I') and (III). The substituted benzaldehydes of formulae (II) and (III) are known compounds or can be prepared from readily available starting materials by conventional methods. The l,4-diacetyl-2,5-piperazinedione used as a starting material in the preparation of compounds of formula (I) may be prepared by treating 2,5-piperazinedione (glycine anhydride) with an acetylating agent. The acetylation may be performed using any conventional acetylating agent, for example acetic anhydride under reflux or, alternatively, acetic anhydride at a temperature below reflux in the presence of 4-dimethylaminopyridine.
Compounds of formula (I) may also be prepared by the microwave irradiation of a mixture comprising 1,4-diacetyl- 2,5-piperazinedione, a compound of formula (III) and potassium fluoride on alumina (as base) in the absence of solvent.
Compounds of formula (I) may alternatively be prepared directly from 2,5-piperazinedione (glycine anhydride) by a process which comprises treating the 2,5- piperazinedione with a mixture comprising a compound of formula (III) , sodium acetate and acetic anhydride at an elevated temperature, for example under reflux.
Compounds of formula (I') may be prepared by analogous processes, replacing compound (III) in each case by a compound of formula (II) . Compounds of formula A may also be prepared by a process comprising the microwave irradiation of (i) a mixture comprising a compound of formula (I) as defined above, a compound of formula (II) and potassium fluoride on alumina, or (ii) a mixture comprising a compound of formula (I') a compound of formula (III) and potassium fluoride on alumina, or (iii) a mixture comprising l,4-diacetyl-2,5- piperazinedione, a compound of formula (II) , a compound of formula (III) and potassium fluoride on alumina. The irradiation is performed in the absence of a solvent. Compounds of formula (A) may also be obtained directly by a process which comprises condensing together l,4-diacetyl-2,5-piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of a base in an organic solvent. Suitable bases, solvents and reaction conditions are as described above for the condensation reaction between, for example, compounds (I) and (II) .
An alternative direct process for the preparation of compounds of formula (A) comprises condensing together 2,5- piperazinedione, a compound of formula (II) and a compound of formula (III) in the presence of sodium acetate and acetic anhydride at elevated temperature, for example under reflux.
An alternative process for the preparation of compounds of formula (I) comprises treating a compound of formula (V) :
wherein R6 to R10 are as defined above, X is a halogen and R' is a C1-C6 alkyl group, with ammonia followed by acetic anhydride. Compounds of formula (I') may be prepared by an analogous process which comprises treating a compound of formula (V )
wherein R1 to Rj, X and R1 are as defined above, with ammonia followed by acetic anhydride.
X in formula (V) or (V) is typically iodine. R1 is, for example, a C,-C4 alkyl group such as a methyl, ethyl, propyl, i-propyl, butyl, sec-butyl or tert-butyl group.
A review of synthetic approaches to unsaturated 3- monosubstituted and 3,6-disubstituted-2,5-piperazinediones is provided in Heterocvcles. 1983, 2J), 1407 (C.Shin) . Compounds of formula (A) may be converted into pharmaceutically acceptable salts, and salts may be converted into the free compound, by conventional methods. Suitable salts include salts with pharmaceutically acceptable, inorganic or organic, bases. Examples of inorganic bases include ammonia and carbonates, hydroxides and hydrogen carbonates of group I and group II metals such as sodium, potassium, magnesium and calcium. Examples of organic bases include aliphatic and aromatic amines such as methylamine, triethylamine, benzylamine, dibenzylamine or α- or β-phenylethylamine, and heterocyclic bases such as piperidine, 1-methylpiperidine and morpholine.
Compounds of formula (A) may also be converted into pharmaceutically acceptable esters. Suitable esters include branched or unbranched, saturated or unsaturated C1-C6 alkyl esters, for example methyl, ethyl and vinyl esters.
Preferred compounds of formula A are depicted by means of their subsitution patterns in Table 1 which follows. The compound numbering is adhered to in the rest of the specification. Characterising data for the compounds are set out in Table 2 in Examole 16. TABLE 1
0) c
CD
9
H C H m 0)
I m m
H
0) c ro
H
H
C H m 0)
I m m
H
0) c
00
H H c m
0)
I m m
0) c
00
Si
H
C H m
CO x m t m
H
The diketopiperazines of formula (A) , both novel and known and their pharmaceutically acceptable salts and esters (referred to hereinafter as the "present compounds") have utility as inhibitors of PAI. Elevated levels of PAI- 1, by reducing the net endogenous fibrinolytic capacity, can contribute to the pathogenesis of various thrombotic disorders including myocardial infarction, deep vein thrombosis and disseminated intravascular coagulation. The present compounds therefore can act as inhibitors of the tPA/PAI-1 interaction. The present compounds can be used in the treatment of haemostatic disorders. A human or animal, e.g. a mammal, can therefore be treated by a method comprising administration of a therapeutically effective amount of a diketopiperazine of formula (A) or a pharmaceutically or veterinarily acceptable salt thereof. Tissue plasminogen activator (tPA) is used as a fibrinolytic agent in the treatment of thrombotic disorders. The efficacy of the tPA in this role may be enhanced if it is administered together with a PAI inhibitor. A human or animal, e.g. a mammal, can therefore be treated by a method comprising the combined administration of a therapeutically effective amount of tPA and a therapeutically effective amount of any one of the present compounds. The present invention also provides products containing a diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof and tPA as a combined preparation for simultaneous, separate or sequential use in the treatment of thrombotic disorders, for example where there is inappropriate PAI activity. In such products the present compound is formulated for oral or parenteral (intravenous, intramuscular or subcutaneous) administration and the tPA is formulated for intravenous administration.
As one example, during acute myocardial infarction (MI) one of the present compounds may be administered to a patient together with tPA to enhance the efficacy of the tPA treatment. As a further example, early re-occlusion following treatment of a patient with tPA may be prevented by the post-MI administration of one of the present compounds. The compounds of formula (A) have been tested in a PAI functional assay. In this assay, a compound is incubated with PAI-1 prior to addition to the tPA assay system. Inhibition of PAI-1 results in the production of plasmin from plasminogen. In turn, plasmin cleaves the chromogenic substrate S2251 (Kabi Vitrum) producing pNA (p- nitroaniline) which is detected spectrophoto etrically at 405 nm (K.Nilsson et al, Fibrinolysis (1987) l , 163-168). The results of the assay are reported in Example 1 which follows. The present compounds can be administered in a variety of dosage forms, for example orally such as in the form of tablets, capsules, sugar- or film-coated tablets, liquid solutions or suspensions or parenterally, for example intramuscularly, intravenously or subcutaneously. The present compounds may therefore be given by injection or infusion.
The dosage depends on a variety of factors including the age, weight and condition of the patient and the route of administration. Typically, however, the dosage adopted for each route of administration when a compound of the invention is administered alone to adult humans is 0.001 to 10 mg/kg, most commonly in the range of 0.01 to 5 mg/kg, body weight. Such a dosage may be given, for example, from 1 to 5 times daily by bolus infusion, infusion over several hours and/or repeated administration.
When one of the present compounds is administered in combination with tPA to adult humans, the dosage adopted for each route of administration is typically from 0.001 to 10 mg, more typically 0.01 to 5 mg per kg body weight for a compound of the invention and from 5 to 500mg administered intravenously for the tPA. A suitable dosage regimen for the tPA is 100 mg given intravenously over 3 hours as follows: 10% of the total dose as an i.v. bolus over 1-2 minutes, 50% of the total dose as an infusion over 1 hour, 40% of the total dose as an infusion over the subsequent 2 hours.
A diketopiperazine of formula (A) or a pharmaceutically acceptable salt or ester thereof is formulated for use as a pharmaceutical or veterinary composition also comprising a pharmaceutically or veterinarily acceptable carrier or diluent. The compositions are typically prepared following conventional methods and are administered in a pharmaceutically or veterinarily suitable form. An agent for use as an inhibitor of PAI comprising any one of the present compounds is therefore provided.
For example, the solid oral forms may contain, together with the active compound, diluents such as lactose, dextrose, saccharose, cellulose, corn starch or potato starch; lubricants such as silica, talc, stearic acid, magnesium or calcium stearate and/or polyethylene glycols; binding agents such as starches, arabic gums, gelatin, methylcellulose, carboxymethylcellulose, or polyvinyl pyrrolidone; disintegrating agents such as starch, alginic acid, alginates or sodium starch glycolate; effervescing mixtures; dyestuffs, sweeteners; wetting agents such as lecithin, polysorbates, lauryl sulphates. Such preparations may be manufactured in known manners, for example by means of mixing, granulating, tabletting, sugar coating, or film-coating processes. Liquid dispersions for oral administration may be syrups, emulsions and suspensions. The syrups may contain as carrier, for example, saccharose or saccharose with glycerol and/or annitol and/or sorbitol. In particular, a syrup for diabetic patients can contain as carriers only products, for example sorbitol, which do not metabolise to glucose or which only metabolise a very small amount to glucose. The suspensions and the emulsions may contain as carrier, for example, a natural gum, agar, sodium alginate, pectin, methylcellulose, carboxymethylcellulose or polyvinyl alcohol. Suspensions or solutions for intramuscular injections may contain, together with the active compound, a pharmaceutically acceptable carrier such as sterile water, olive oil, ethyl oleate, glycols such as propylene glycol, and, if desired, a suitable amount of lidocaine hydrochloride. Some of the present compounds are insoluble in water. A compound may be encapsulated within liposomes.
The following Examples illustrate the invention:
EXAMPLE 1 t TESTING OF THE PRESENT
COMPOUNDS AS PAI INHIBITORS
Compounds of formula (A) were tested in a PAI chromogenic substrate assay. In the first assay (K.Nilsson, Fibrinolysis (1987) 1 , 163-168) each compound was incubated with PAI-1 prior to addition to the tPA assay system. Inhibition of PAI-1 by the compound of formula (Aa) resulted in the production of plasmin from plasminogen. In turn, the plasmin cleaved the chromogenic substrate S2251 (Kabi-Vitrum) producing pNA (p_- nitroaniline) which was detected spectrophotometrically at 405 nm.
The degrees of inhibition observed in the chromogenic substrate assay at various concentrations of compounds of formula (A) are presented in Table 3. 2
- 28 -
2
- 30 -
EXAMPLE 2 I PHARMACEUTICAL COMPOSITION Tablets, each weighing 0.15 g and containing 25 mg of a compound of the invention can be manufactured as follows: Composition for 10.000 tablets compound of the invention (250 g) lactose (800 g) corn starch (415 g) talc powder (30 g) magnesium stearate (5 g)
The compound of the invention, lactose and half of the corn starch are mixed. The mixture is then forced through a sieve 0.5 mm mesh size. Corn starch (10 g) is suspended in warm water (90 ml) . The resulting paste is used to granulate the powder. The granulate is dried and broken up into small fragments on a sieve of 1.4 mm mesh size. The remaining quantity of starch, talc and magnesium stearate is added, carefully mixed and processed into tablets.
EXAMPLE 3; PREPARATION OF (3Z.6Z)-3-BENZYLIDBNE-
6-(4-METHOXYBENZYLIDENE) -2.5-PIPERAZINEDIONE (3) (SCHEME 1)
1.4-Diacetyl-2.5-piperazinedione (8) l,4-Diacetyl-2,5-piperazine-2,5-dione (8) was prepared by the published procedure (S.M. Marcuccio and J.A. Elix, Aust. J. Chem.. 1984, 37, 1791).
(3Z)-l-Acetyl-3-(4-methoxybenzylidene) -2.5-piperazinedione (9) (3Z)-l-Acetyl-3-(4-methoxybenzylidene)-2,5- piperazinedione (9) was prepared by the published procedure (T. Yokoi, L-M. Yang, T. Yokoi, R-Y. Wu, and K-H. Lee, J. Antibiot.. 1988, 41, 494).
(3Z.6Z)-3-Benzylidene-6-(4-methoxybenzylidene)-2.5- piperazinedione (3)
A mixture of (3Z) -l-acetyl-3-(4-methoxybenzylidene)- 2,5-piperazinedione (9) (l.Og, 3.6 mmol), benzaldehyde (430 μl, 4.2 mmol) and triethylamine (1.14 ml), 8.2 mmol), in dry DMF (20 ml), was heated at 130'C for 18h. The reaction mixture was cooled to room temperature and poured into ethyl acetate (100 ml) . A yellow solid precipitated which was filtered off and dried. Yield 360 mg (31%) . C19H16N203 1H nmr (400 MHz d6-DMSO) :
<S: 3.80 (3H, s, o-Me) ; 6.77 (1H, s, CH=C) ;
6.78 (1H, s, CH=C) ; 6.98 (2H, d, J=8Hz , 2XC-H on Ar- OMe) ; 7.30-7.56 (7H, m, Ph and 2xC-H on Ar-OMe) ; 10.15 (2H, br.s, N-H) . 13C nmr (100 MHz d6-DMSO)
<S: 58.68; 117.66; 118.03; 118.77; 128.11; 128.92; 129.95; 131.53; 132.11; 132.69; 134.44; 136.59; 161.39; 161.62; 162.71. ms (desorption chemical ionisation, ammonia) : m/z (% relative intensity) : 321 (100) MH*. ir : KBr (diffuse reflectance) : v max (cm'1) : 1620, 1700, 3100, 3220. Elemental analysis:
Calculated for C19H16N203: C 71.24, H 5.03, N 8.74. Found: C 70.92, H 5.02, N 8.80.
C 70.89, H 5.06, N 8.79% EXAMPLE 4: PREPARATION OF (3Z.6Z)-3-BENZYLIDENE -6-(4-METHOXYBENZYLIDENE)-l-METHYL-2.5-PIPERAZINEDIONE (1)
(SCHEME 2)
(16) (17)
Compound 16 is treated with ammonia and subsequently with acetic anhydride to yield l-acetyl-3- benzylidenepiperazine-2,5-dione (18) .
Compound 18 is then condensed, in the presence of caesium carbonate or triethylamine in DMF, with 4- methoxybenzaldehyde to yield compound 3.
Reference Example 1: Preparation of l-acetyl-3- benzylidene-2.5-piperazinedione
l,4-Diacetyl-2,5-piperazinedione (25.0g, 126 mmol), which is compound (8) mentioned in Example 3, was heated at 120-130*C in DMF (200 ml) with triethylamine (17.6 ml, 126 512
- 34 - mmol) and benzaldehyde (13.0 ml, 126 mmol) . After 4 h the mixture was cooled to room temperature and poured into EtOAc (1000 ml) , and washed three times with brine. Any solid formed at this stage was filtered off. The filtrate was dried (MgSO and the solvent removed in vacuo. The residue was recrystallised from EtOAc:Hexane to give 11.78 g (38%) of the title compound as a yellow solid.
• NMR (CDClj 400 MHz) <5=2.69 (3H, s) 4.54 (2H, s) 7.20 (1H, ε) 7.40 (3H, m) , 7.48 (2H, m) ,
7.93 (1H, br.s)
MS(DCI,NH3): 262 (MNHA\ 20%), 245 (MH*, 53%),
220 (52%), 204 (100%), 203 (100%)
Example 5: Preparation of compound 96 l-Acetyl-3-benzylidene-2,5-piperazinedione (one equivalent), prepared according to Reference Example 1, waε treated with 5-(4-formylphenoxy)pentanoic acid, methyl ester in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80-100*C for 1-8 hours. The title compound was obtained in 39% yield.
By the same method, but replacing 5-(4- formylphenoxy)pentanoic acid, methyl ester (which is benzaldehyde substituted at position 4 by -OfCH- ^COjMe) by the appropriately substituted benzaldehyde, the following compounds were prepared:
512
- 35 -
Characterising data for the compounds are set out in Example 16.
Example 6: Preparation of Compound 31 l-Acetyl-3-benzylidene-2,5-piperazinedione (one equivalent) , prepared according to Reference Example 1, was treated with 3-acetoxybenzaldehyde (one equivalent) in the presence of triethylamine (1-2 equivalents) in DMF at 130*C for 2-6 hours. The title compound was obtained in 61% yield. By the same method, but replacing 3- acetoxybenzaldehyde by the appropriately substituted benzaldehyde, the following compounds were prepared:
Characterising data are provided in Example 16.
Example 7: Preparation of compound 103 l-Acetyl-3-(4-methoxybenzylidene)-2,5-piperazinedione (1 equivalent) , which is compound (9) mentioned in Example 3, was treated with 2-fluorobenzaldehyde (1 equivalent) in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80- 100°C for 1-6 hours. The title compound was obtained in 69% yield.
By the same method, but replacing the 2- fluorobenzaldehyde by the appropriately substituted benzaldehyde with the exception of compound 84 which was prepared by condensation with 4-acetoxy-2- chlorobenzaldehyde, the following compounds were prepared:
Characterising data are provided in Example 16.
Example 8: Preparation of compound 28 l-Acetyl-3-(4-methoxybenzylidene)-2,5-piperazinedione (1 equivalent), compound (9) in Example 3, was treated with 2-nitrobenzaldehyde (1 equivalent) in triethylamine (1-2 equivalents) and DMF at 130 " C for 2-6 hours. The title compound was obtained in 45% yield. Characterising data are set out in Example 16. Referept-ft By-am le 2: Preparation of l-acetyl-3-(4- acetamidobenzylidene)-2,5- pjperazinedione l,4-Diacetyl-2,5-piperazinedione (10.0g, 50 mmol), prepared by the published procedure mentioned in Example 3, was stirred in DMF (40 ml) with 4-acetamidobenzaldehyde (8.24 g, 50 mmol) and triethylamine (7 ml, 50 mmol) and heated to 120 ° C. After 2 h the mixture was cooled to room temperature, diluted with EtOAc (100 ml) and stirred overnight. The solid formed was collected, washed with EtOAc and dried to give 8.46 g (56%) of a yellow solid.
1H NMR (CDC13+TFA, 400 MHz) .5=2.32 (3H, s) 2.72 (3H, s) 4.68 (2H, s) 7.36 (IH, s) 7.45 (2H, d, J=8Hz) 7.60 (2H, d, J=8HZ)
Example 9; Preparation of Compound 77 l-Acetyl-3-(4-acetamidobenzylidene)-2,5- piperazinedione (1 equivalent) , prepared according to Reference Example 2, was treated with 2,4- difluorobenzaldehyde (1 equivalent) in the presence of Cs2C03 (1-1.1 equivalents) in DMF at 80-100"C for 1-6 hours. The title compound was obtained in 60% yield. By the same method, but replacing 2,4- difluorobenzaldehyde by the appropriately substituted benzaldehyde, the following compounds were obtained:
Characterising data are set out in Example 16.
Example 10: Preparation of compound 22 l,4-Diacetyl-2,5-piperazinedione (1 equivalent), prepared by the published procedure mentioned in Example 3, was treated with benzaldehyde (2.1 equivalents) in the presence of triethylamine (2.5 equivalents) in DMF at 130βC for 8 hours. The title compound was obtained in 89% yield. Characterising data are set out in Example 16.
Example 11; Preparation of compound 35 l,4-Diacetyl-2,5-piperazinedione (1 equivalent), prepared by the published procedure mentioned in Example 3, was treated with 3-nitrobenzaldehyde (1 equivalent) in the presence of triethylamine (1 equivalent) in DMF at room temperature for 18-20 hrs. The title compound was obtained in 9% yield together with l-acetyl-3-(3-nitrobenzylidene)- 2,5-piperazinedione (66% yield). Characterising data are set out in Example 16.
Reference Bvumpie 3: Preparation of l-acetyl-3-(4-N,N- dimethγlaminobenzylidine)-2.5- piperazinedione l,4-Diacetyl-2,5-piperazinedione, (1 equivalent), prepared as described in Example 3, was treated with 4-N,N- dimethylaminobenzaldehyde (1 equivalent) in the presence of Et3N in DMF at 130βC for 24 hrs. The title compound was obtained in 18% yield
Example 12: Preparation of Compound 86 l-Acetyl-3-(4-dimethylaminobenzylidene)-2,5- piperazinedione (1 equivalent) as described in Reference Example 3 was treated with 4-acetamidobenzaldehyde (1 equivalent) in the presence of Cs2C03 (1 equivalent) in DMF at 80*C for 2-6 hours. The title compound was obtained in 56% yield. Characterising data are set out in Example 16.
R awpift 13; Intβrconversions of compounds of formula
(i) Compound 31, prepared as described in Example 6, was treated with aqueous lithium hydroxide in a mixture of MeOH and THF at room temperature for 2-3 hrs to give compound 33 in 91% yield.
(ii) Compound 61, prepared as described in Example 5, was treated with aqueous lithium hydroxide in a mixture of MeOH and THF at room temperature for 3 hours to give compound 64 in 57% yield. (iii) Compound 96, prepared as described in Example 5, was treated with aqueous sodium hydroxide in THF at room temperature for 4 hours to give compound 97 in 54% yield.
(iv) Compound 37, prepared as described in Example 7, was treated with aqueous sodium hydroxide in THF at room temperature for 8 hrs to give compound 36 in 30% yield.
(v) Compound 56, prepared as described in Example 7, was treated with trifluoroacetic acid in CH2C12 at room temperature for 12 hrs to give compound 67 in 96% yield.
(vi) Compound 87, prepared as described in Example 7, was treated with aqueous sodium hydroxide in THF at room temperature for 4 hours to give compound 88 in 69% yield.
(vii) Compound 65, prepared as described in Example 6 was hydrogenated over 10% palladium on carbon as catalyst in
CH2C12 in the presence of a few drops of trifluoroacetic acid to give compound 39 in 38% yield. Under the same conditions of hydrogenation compound 74 was converted into compound 30 in 95% yield.
(viii) Compound 93, prepared as described in Example 5, waε hydrolysed by treatment with aqueous sodium hydroxide in a mixture of MeOH and THF at room temperature for 18 hours to give compound 101 in 72% yield.
(ix) Compound 58, prepared as described in Example 9, waε hydrolysed by treatment with aqueous sodium hydroxide in THF at room temperature for 3 hours to give compound 104 in 90% yield.
Characterising data for all compounds prepared in this Example are provided in Example 16.
gymn i i » Preparation of Compound 27 l-Acetyl-3-(4-methoxybenzylidene)-2,5- piperazinedione (1 equivalent), compound (9) in Example 3, was treated with 2-naphthaldehyde (1 equivalent) in the presence of Cs2C03 (1.0-1.1 equivalents) in DMF at 80-100*C for 1-6 hours. The title compound was obtained in 84% yield.
Characterising data are provided in Example 16.
Example 15; Preparation of Salts
Compound 98, the hydrochloride salt of compound 102, was prepared by treatment of a solution of compound 102 in THF with 2 molar hydrochloric acid followed by sonication until a clear solution was obtained. The solvent was then removed in vacuo and the residual solution was freeze-dried to give compound 98.
Compound 99 was prepared by bubbling HCl gas through a solution of the corresponding free base in THF, followed by evaporation to dryness.
Characterising data are provided in Example 16.
T_ynir.pla i«;« Characterization of compounds of formula A The compounds prepared in the preceding Examples, were characterised by mass spectroscopic, microanalytical, proton nuclear magnetic resonance and, in some cases, infra-red techniques. The results are set out in Table 2: TABLE 2
0) c
CD
0)
H
H
C H m
0) z m m
0) c
DO
15
H
C
H m
(0 x m m
H
0) c
CD
ϋ m
0)
I m
H
0) c
CO
c
H m
0)
I m m
0) c
H
C -I m CD
(0 x m m
H
SUBSTITUTE SHEET
SUBSTITUTE SHEET
SUBSTITUTE SHEET I
0) c co
0)
H
C
H m
0)
I m m
H
SUBSTITUTE SHEET
0) c
DO CO
H
H 0^
C
H m co
I m m
H
CD
C m co
H
C H m co x m
H
SUBSTITUTE SHEET

Claims

1. A diketopiperazine of formula (A) :
wherein each of R1 to R10, which may be the same or
different, is independently selected from hydrogen, C1-C6 alkyl unsubstituted or substituted by one or more halogen atoms, C1-C6 alkoxy, C1-C6 alkylthio, halogen, hydroxy, nitro, optionally substituted phenyl, -cyano, -CH2OH,
-CH2COOH, -CO2R11, -NHCOR11, -NHSO-R13, -SO2R13, -CON(R11R12), -SOR13, -SO2N(R11R12), -N(R11R12), -O(CH2)nN(R11R12),
-O(CH2)nCO2R11, -OCOR11, -CH2OCOR11, -CH2NHCOR11, -CH2NHCOOR13, -CH2SR11, -CH2SCOR11, -CH2S(O)mR13 wherein m is 1 or 2,
-CH2NHCO(CH2)nCO2R11, -N (R11)COR12, -NHCOCF3, -NHCO(CH2)nCO2R11, -NHCO(CH2)nOCOR11 and -NHCO(CH2)nOR11 wherein n is O or is an integer of from 1 to 6, each of R11 and R12 is independently H or C1-C6 alkyl and R13 is C1-C6 alkyl; or any of R1 and R2, R2 and R3, R3 and R4 and R4 and R5, or R6 and R7, R7 and R8, R8 and R9 and R9 and R10, form together with the carbon atoms to which they are attached a benzene ring which is
optionally substituted; or a pharmaceutically acceptable salt or ester thereof; with the exception of compounds wherein:
(i) each of R1 to R10 is H;
(ii) R1 and R6 are both Cl and the rest of R2 to R10 are H; R2 and R7 are both Cl and the rest of R1 to R10 are H; R3 and R8 are both Me and the rest of R1 to R10 are H; R2 R5, R7 and R10 are all Me and the rest of R1 to R10 are H; R2,
R3, R4, R7, R8 and R9 are all OMe and R1, R5, R6 and R10 are H;
(iii) R8 is OMe and the rest of R1 to R10 are H; and (iv) 3-p-nitrobenzylidene-6-benzylidene-2,5-piperazinedione and 3,6-di-p-nitrobenzylidene-2,5-piperazinedione.
2. A compound according to claim 1 wherein one of R6 to R10 is selected from halogen, alkoxy and -NHCOR11 and the other four of R6 to R10 are H.
3. A compound according to claim 2 wherein R8 is selected from halogen, alkoxy and -NHCOR11 and R6, R7, R9 and R10 are H.
4. A compound according to any one of the
preceding claims wherein R1 and R2 are independently H, nitro or halogen; R3 is H, hydroxy, -O(CH2)nN(R11R12),
-OCOR11, -O(CH2)nCO2R11, -CH2NHCO(CH2)nCO2R11, C1-C6 alkoxy, -NHCO(CH2)nOR11, -NHCO (CH2) OCOR11, -N(R11R12) , -CH2NHCO2R13, -CH2SR11 or NHCOR11; R4 is H, halogen, C1-C6 alkoxy,
-CH2SCOR11, CH2SR11 or -CO2R11 and R5 is H, nitro or halogen.
5. A compound according to any one of claims 1 to 3 wherein R2 and R3, R3 and R4, or R4 and R8 form, together with the carbon atoms to which they are attached, an optionally substituted benzene ring.
6. A compound according to any one of claims 1 to 3 wherein R8 is -NHAc wherein Ac is acetyl, R1 is H or halogen; R2 is H, R3 is halogen, C1-C6 alkoxy, -N(R11R12) or -NHCOOR13; R4 is H, ; R8 is halogen or CF3; and R6, R7, R9 and R10 are H.
7. A compound according to any one of claims l to 3 wherein R8 is OMe, R1 is H, nitro or halogen; R2 is H; R3 is H, hydroxy, -OCOR11, -NHCO(CH2)nOCOR11 or -NHCOCH2OR11; or R2 and R3 form, together with the carbon atoms to which they are attached, a benzene ring; R4 is H; R8 is H or halogen; and R6, R7, R9 and R10 are H.
8. A compound according to any one of claims 1 to 3 wherein R1, R6, R7, R8, R9 and R10 are H; R2 is H and R3 is -CH2SR11, -CH2SCOR11, -NHCO(CH2) nCO2R11, -O(CH2) nCO2R11,
-O(CH2)nN(R11R12), or -N(R11R12) or R2 is -CH2SCOR13 or
-CH2SR11 and R3 is H; and R4 and R8 are both H or form, together with the carbon atoms to which they are attached, a benzene ring.
9. A compound according to claim 1 selected from (3Z,6Z,)-3-benylidene-6-(4-methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(2,6-dichlorobenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Acetoxybenzylidene)-6-benzylidene-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-nitrobenzylidene)-2,5-piperazinedione
3,6-Dibenzylidene-2,5-piperazinedione (mixture of isomers) (3Z,6Z)-6-Benzylidene-3-(3-nitrobenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(2-nitrobenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-ethoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-cyanobenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Aminobenzylidene)-6-benzylidene-2,5-piperazinedione
(3Z,6Z)-3-(3-Acetoxybenzylidene)-6-benzylidene-2,5- piperazinedione
(3Z,6Z)-3-(2-Acetoxybenzylidene)-6-benzylidene-2,5- piperazinedione
(3Z,6Z)-6-Benzylidene-3-(3-hydroxybenzylidene)-2,5- piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-benzylidene-2,5- piperazinedione
(3Z,6Z)-3-(2-Acetamidobenzylidene)-6-benzylidene-2,5- piperazinedione
(3Z,6Z)-3-(2-Aminobenzylidene)-6-benzylidene-2,5- piperazinedione
(3Z,6Z)-3-(4-Acetoxymethylbenzylidene)-6-benzylidene-2,5- piperazinedione
(3Z,6Z)-3-(4-Acetamidomethylbenzylidene)-6-benzylidene-2,5- piperazinedione (3Z,6Z)-3,6-Dibenzylidene-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-butoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-tert-butylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-isopropoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(2,4-difluorobenzylidene)-2,5-piperazinedione
(3Z , 6Z) -6-Benzylidene-3- (2-bromobenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-methylthiomethylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(3-thioacetoxymethylbenzylidene)-2,5-piperazinedione
3-((3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3-ylidene)methylbenzoic acid, methyl ester
(3Z,6Z)-6-Benzylidene-3-(3-mercaptomethylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-tert-butoxycarbonylaminobenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-(3-N,N-dimethylaminopropoxy)benzylidene)-2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(4-thioacetoxymethylbenzylidene)- 2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(2-chloro-4-hydroxybenzylidene)- 2,5-piperazinedione
(3Z,6Z)-6-Benzylidene-3-(3,4-dimεthoxybenzylidene)-2,5-piperazinedione
4-[(3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene]methylphenoxyacetic acid, methyl ester
4-(4-[(3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene]methylbenzylcarbamoyl) butanoic acid, methyl ester 4-(4-((3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene)methylbenzylcarbamoyl)pentanoic acid, methyl ester 5-[4-((3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3- ylidene)methylphenoxy]pentanoic acid, methyl ester 5-[4-((3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3-ylidene)methylphenoxy]pentanoic acid
(3Z,6Z)-6-Benzylidene-3-(4-(2-N,N-dimethylaminoethoxy)benzylidene)-2,5-piperazinedione,hydrochloride
(3Z,6Z)-6-Benzylidene-3-(4-(2-N,N-dimethylaminoethoxy)benzylidene)-2,5-piperazinedione
4-[(3Z,6Z)-6-Benzylidene-2,5-dioxopiperazin-3-ylidene]methylphenoxyacetic acid
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-(4-Methoxybenzylidene)-3-(2-nitrobenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(2,6-Dichlorobenzylidene)-6-(4-methoxybenzylidene)-2 ,5-piperazinedione
(3Z,6Z)-3-(4-Hydroxybenzylidene)-6-(4-methoxybenzylidene)- 2,5-piperazinedione
(3Z,6Z)-3-(4-Acetoxybenzylidene)-6-(4-methoxybenzylidene)- 2,5-piperazinedione
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4-N- methylacetamidobenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4- methylsulfonylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Butoxybenzylidene)-6-(4-methoxybenzylidene)- 2,5-piperazinedione
(3Z,6Z)-3-(4-isopropoxybenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-methoxybenzylidene)-6-(4-tert- butylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(2-Bromobenzylidene)-6-(4-methoxybenzylidene)- 2,5-piperazinedione
(3Z,6Z)-(4-Methoxybenzylidene)-6-(4-tert- butoxycarbonylaminomethylbenzylidene)-2,5-piperazinedione (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4- methylthiomethylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4- methylsulfonylmethylbenzylidene)-2,5-piperazinedione (3Z,6Z)-3-(4-Methoxybenzylidene)-6-(3-thioacetoxymethylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Aminomethylbenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(2,4-Difluorobenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(2-trifluoromethylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(2,4-Dimethoxybenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione
4-[(3Z,6Z)-6-(4-Methoxybenzylidene)-2,5-dioxopiperazin-3-ylidene] methylbenzamide
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4-trimethylacetoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(4-methoxycarbonylaminobenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(2-Chloro-4-hydroxybenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Acetoxyacetylaminobenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(3,4-Dimethoxybenzylidene)-6-(4-methoxybenzylidene)-2,5-piperazinedione
4-((3Z,6Z)-6-(4-Methoxybenzylidene)-2,5-dioxopiperazin-3- ylidene)-4-methylbenzylcarbamoyl)butanoic acid, methyl ester
(3Z,6Z)-3-(4-Methoxybenzylidene)-6-(2-naphthylmethylene)- 2,5-piperazinedione
(3Z,6Z)-3-(4-Hydroxyacetylaminobenzylidene)-6-(4- methoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-benzylidene-2,5- piperazinedione
(3Z,6Z)-3,6-Di-(3-Nitrobenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(2,6- dichlorobenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-chlorobenzylidene)- 2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4- acetoxymethylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(2-fluorobenzylidene)- 2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-fluorobenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-(Benzylidene)-3-(2,4-difluorobenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-(4-Acetamidobenzylidene)-3-(2-trifluoromethylbenzylidene)-2,5-piperazinedione
(3Z,6Z)-6-(4-Acetamidobenzylidene)-3-(2-bromobenzylidene)- 2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-trimethylacetoxybenzylidene)-2,5-piperazinedione
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-dimethylaminobenzylidene)-2,5-piperazinedione; and
(3Z,6Z)-3-(4-Acetamidobenzylidene)-6-(4-tert-butoxycarbonylaminomethylbenzylidene)-2,5-piperazinedione
10. A pharmaceutical or veterinary composition comprising a pharmaceutically or veterinarily acceptable carrier or diluent and, as an active principle, a compound as claimed in any one of the preceding claims.
11. A process for preparing a compound of formula (A) as defined in claim 1, the process comprising:
(a) condensing a compound of formula (I):
wherein R6 to R10 are as defined in claim 1 and are optionally protected, with a compound of formula (II):
wherein R1 to R8 are as defined in claim 1 and are
optionally protected, in the presence of a base in an organic solvent; or
(b) condensing a compound of formula (I'):
wherein R1 to R8 are as defined in claim 1 and are
optionally protected with a compound of formula (III):
wherein R6 to R10 are as defined in claim 1 and are
optionally protected, in the presence of a base in an organic solvent; and
(c) if required, removing optionally present protecting groups, and/or, if desired, converting one compound of formula A into another compound of formula A, and/or, if desired, converting a compound of formula A into a pharmaceutically acceptable salt or ester thereof, and/or, if desired, converting a salt or ester into a free compound, and/or, if desired, separating a mixture of isomers into the single isomers.
12. A compound as defined in any one of claims 1 to 9 for use as an inhibitor of plasminogen activator inhibitor.
13. Use of a diketopiperazine of formula (A):
wherein each of R1 to R10, which may be the same or
different, is independently selected from hydrogen, C1-C6 alkyl unsubstituted or substituted by one or more halogen atoms, C1-C6 alkoxy, C1-C6 alkylthio, halogen, hydroxy, nitro, optionally substituted phenyl, cyano, -CH2OH,
-CH2COOH, -CO2R11, -NHCOR11, -NHSO2R13, -SO2R13, -CON(R11R12), -SOR13, -SO2N(R11R12) , -N(R11R12), -O(CH2)pN(R11R12),
-O(CH2)nCO2R11, -OCOR11, -CH2OCOR11, -CH2NHCOR11, -CH2NHCOOR13, -CH2SR11, -CH2SCOR11, -CH2S(O)mR13 wherein n is 1 or 2,
-CH2NHCO(CH2)nCO2R11, -N(R11)COR12, -NHCOCF3, -NHCO(CH2)nCO2R11, -NHCO(CH2)nOCOR11 and -NHCO(CH2)nOR11 wherein n is O or an integer of from 1 to 6, each of R11 and R12 is independently H or C1-C6 alkyl and R13 is C1-C6 alkyl; or any of R1 and R2, R2 and R3, R3 and R4 and R4 and R8, or R6 and R7, R7 and R8, R8 and R9 and R9 and R10, form together with the carbon atoms to which they are attached a benzene ring which is
optionally substituted; or a pharmaceutically acceptable salt or ester thereof; in the manufacture of a medicament for use as an inhibitor of plasminogen activator inhibitor.
14. Use according to claim 13, wherein the
compound is a compound as defined in any of claims 1 to 9.
EP93918032A 1992-08-14 1993-08-16 Pharmaceutically active diketopiperazines Expired - Lifetime EP0655060B1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB929217331A GB9217331D0 (en) 1992-08-14 1992-08-14 Pharmaceutical compounds
GB9217331 1992-08-14
PCT/GB1993/001734 WO1994004512A1 (en) 1992-08-14 1993-08-16 Pharmaceutically active diketopiperazines

Publications (2)

Publication Number Publication Date
EP0655060A1 true EP0655060A1 (en) 1995-05-31
EP0655060B1 EP0655060B1 (en) 1998-01-14

Family

ID=10720385

Family Applications (2)

Application Number Title Priority Date Filing Date
EP93918032A Expired - Lifetime EP0655060B1 (en) 1992-08-14 1993-08-16 Pharmaceutically active diketopiperazines
EP93918033A Ceased EP0672036A1 (en) 1992-08-14 1993-08-16 Pharmaceutically active diketopiperazines

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP93918033A Ceased EP0672036A1 (en) 1992-08-14 1993-08-16 Pharmaceutically active diketopiperazines

Country Status (24)

Country Link
US (1) US5700804A (en)
EP (2) EP0655060B1 (en)
JP (2) JPH08504175A (en)
KR (2) KR950702967A (en)
AT (1) ATE162186T1 (en)
AU (2) AU678172B2 (en)
BG (2) BG99496A (en)
BR (2) BR9306904A (en)
CA (2) CA2141938A1 (en)
CZ (2) CZ38395A3 (en)
DE (1) DE69316370T2 (en)
DK (1) DK0655060T3 (en)
ES (1) ES2111169T3 (en)
FI (2) FI950616A (en)
GB (2) GB9217331D0 (en)
GR (1) GR3026272T3 (en)
HU (2) HUT71593A (en)
IL (2) IL106696A0 (en)
PL (2) PL307438A1 (en)
RU (2) RU95108759A (en)
SK (2) SK19595A3 (en)
TW (1) TW334427B (en)
WO (2) WO1994004512A1 (en)
ZA (2) ZA935968B (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555543B2 (en) 2000-08-04 2003-04-29 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7575929B2 (en) 2002-10-02 2009-08-18 Dmi Life Sciences, Inc. Diagnosis of multiple sclerosis with diketopiperazines
US9623072B2 (en) 2011-10-10 2017-04-18 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US9707227B2 (en) 2003-05-15 2017-07-18 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US9925300B2 (en) 2011-10-10 2018-03-27 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US9956217B2 (en) 2014-08-18 2018-05-01 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US10357491B2 (en) 2015-03-06 2019-07-23 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US11045467B2 (en) 2015-03-06 2021-06-29 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US11229642B2 (en) 2016-06-06 2022-01-25 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
US11254657B2 (en) 2015-07-13 2022-02-22 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds
DK85193D0 (en) 1993-07-16 1993-07-16 Cancerforskningsfondet Af 1989 SUPPRESSION OF INHIBITORS
GB9402805D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
IL112627A0 (en) * 1994-02-14 1995-05-26 Xenova Ltd Diketopiperazines, their preparation and pharmaceutical or veterinary compositions containing them
GB9402809D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9402807D0 (en) * 1994-02-14 1994-04-06 Xenova Ltd Pharmaceutical compounds
GB9410387D0 (en) * 1994-05-24 1994-07-13 Xenova Ltd Pharmaceutical compounds
GB9426090D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB2311781B (en) * 1994-12-23 1998-09-16 Xenova Ltd Piperazine 2,5 dione derivatives as modulators of multi-drug resistance
GB2310854B (en) * 1994-12-23 1998-09-09 Xenova Ltd Piperazine-2,5-dione derivatives as modulators of multi-drug resistance
GB9426224D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
GB9426071D0 (en) * 1994-12-23 1995-02-22 Xenova Ltd Pharmaceutical compounds
US5891877A (en) * 1995-02-14 1999-04-06 Xenova Limited Pharmaceutical compounds
EP1242379A1 (en) * 1999-12-03 2002-09-25 Emory University Curcumin analogues for treating cancer
US7288545B2 (en) * 2000-05-09 2007-10-30 Angiorx Corporation Piperazinedione compounds
EP1282609B1 (en) 2000-05-09 2008-12-17 AngioRx Corporation Piperazinedione compounds
ES2294026T3 (en) 2000-09-06 2008-04-01 Ap Pharma, Inc. DEGRADABLE POLYACETAL POLYMERS.
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
WO2002062797A2 (en) * 2000-12-29 2002-08-15 Celltech R & D, Inc. Pharmaceutical uses and synthesis of diketopiperazines
GB2372740A (en) * 2001-01-17 2002-09-04 Xenova Ltd Diketopiperazines
US20060229239A9 (en) * 2002-03-08 2006-10-12 Mamoru Shoji Novel curcuminoid-factor VIIa constructs as suppressors of tumor growth and angiogenesis
US7919497B2 (en) 2002-08-02 2011-04-05 Nereus Pharmaceuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
US7935704B2 (en) 2003-08-01 2011-05-03 Nereus Pharmaceuticals, Inc. Dehydrophenylahistins and analogs thereof and the synthesis of dehydrophenylahistins and analogs thereof
DE60316688T2 (en) 2002-08-02 2008-07-17 Nereus Pharmaceuticals, Inc., San Diego DEHYDROPHENYLAHISTINES AND ANALOGS THEREOF AND A PROCESS FOR THE PRODUCTION OF DEHYDROPHENYLAHISTINES AND ANALOGUE THEREOF
DE10238144A1 (en) * 2002-08-15 2004-02-26 Basf Ag Use of aryl-substituted 3,6-dialkylidene-2,5-piperazinedione derivatives as photostable UV filters in cosmetic or pharmaceutical compositions for protecting human skin or hair against solar radiation
GB0314738D0 (en) 2003-06-24 2003-07-30 Glaxo Group Ltd Novel compounds
US7732605B2 (en) 2005-03-29 2010-06-08 Nereus Pharmaceuticals, Inc. Synthesis of diketopiperazines
US20070270464A1 (en) * 2006-02-24 2007-11-22 Emory University Prodrugs of curcumin analogs
US8129527B2 (en) 2006-11-03 2012-03-06 Nereus Pharmacuticals, Inc. Analogs of dehydrophenylahistins and their therapeutic use
JP5856843B2 (en) 2008-05-27 2016-02-10 アンピオ ファーマシューティカルズ，インコーポレイテッド Pharmaceutical composition using diketopiperazine
CA2810844C (en) 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
SG10201802008TA (en) * 2011-02-10 2018-04-27 Mannkind Corp Formation of n-protected bis-3,6-(4-aminoalkyl) -2,5,diketopiperazine
CN103396372B (en) * 2013-08-09 2015-05-20 中国科学院南海海洋研究所 2,5-diketopiperazine derivative, as well as preparation method and application thereof in preparing control agent for resisting marine fouling organisms
CN105272968B (en) * 2014-06-10 2018-03-13 首都医科大学 The diketone of (3S, 6R) 3,6 disubstituted piperazine 2,5, it is prepared and application
CN104610170B (en) * 2015-01-14 2017-02-01 中国科学院南海海洋研究所 2, 5-diketopiperazine derivative as well as preparation method and application thereof
JP2020514412A (en) 2017-02-01 2020-05-21 ビヨンドスプリング ファーマシューティカルズ，インコーポレイテッド Methods for reducing neutropenia
CN110054619A (en) * 2018-01-18 2019-07-26 西北农林科技大学 Novel diketopiperazine histone deacetylases inhibitor
WO2021195265A1 (en) 2020-03-24 2021-09-30 Ampio Pharmaceuticals, Inc. Methods for treating diseases associated with respiratory viruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE621862C (en) * 1932-07-01 1935-11-14 Guenther Schiemann Dr Process for the preparation of condensation products of nucleus fluorinated aryl aldehydes
BE584914A (en) * 1958-11-24
JPS5747357A (en) * 1980-09-04 1982-03-18 Ricoh Co Ltd Novel disazo compound and its preparation
GB9217331D0 (en) * 1992-08-14 1992-09-30 Xenova Ltd Pharmaceutical compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BENZOIC ACID' page 511 ;column 1 ; *
CHEMICAL ABSTRACTS, vol. 98, no. 28, 1983, Columbus, Ohio, US; abstract no. 160674z, IAN RAE ET AL. 'THE REACTION OF PIPERAZINES-2,5-DIONES WITH 2-FORMYL *

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6555543B2 (en) 2000-08-04 2003-04-29 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US10039760B2 (en) 2000-08-04 2018-08-07 Ampio Pharmaceuticals, Inc. Method of using diketopiperazines and composition containing them
US7575929B2 (en) 2002-10-02 2009-08-18 Dmi Life Sciences, Inc. Diagnosis of multiple sclerosis with diketopiperazines
US9730924B2 (en) 2003-05-15 2017-08-15 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US9707227B2 (en) 2003-05-15 2017-07-18 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US11369598B2 (en) 2003-05-15 2022-06-28 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US10828296B2 (en) 2003-05-15 2020-11-10 Ampio Pharmaceuticals, Inc. Treatment of T-cell mediated diseases
US9925300B2 (en) 2011-10-10 2018-03-27 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US9623072B2 (en) 2011-10-10 2017-04-18 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US10251930B2 (en) 2011-10-10 2019-04-09 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US11058798B2 (en) 2011-10-10 2021-07-13 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US10471178B2 (en) 2011-10-10 2019-11-12 Ampio Pharmaceuticals, Inc. Implantable medical devices with increased immune tolerance, and methods for making and implanting
US10842847B2 (en) 2011-10-10 2020-11-24 Ampio Pharmaceuticals, Inc. Treatment of degenerative joint disease
US10881710B2 (en) 2011-10-28 2021-01-05 Ampio Pharmaceuticals, Inc. Treatment of rhinitis
US11026940B2 (en) 2013-03-15 2021-06-08 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US9808454B2 (en) 2013-03-15 2017-11-07 Ampio Pharmaceuticals, Inc. Compositions for the mobilization, homing, expansion and differentiation of stem cells and methods of using the same
US9956217B2 (en) 2014-08-18 2018-05-01 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11090301B2 (en) 2014-08-18 2021-08-17 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US10342793B2 (en) 2014-08-18 2019-07-09 Ampio Pharmaceuticals, Inc. Treatment of joint conditions
US11045467B2 (en) 2015-03-06 2021-06-29 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US10357491B2 (en) 2015-03-06 2019-07-23 Beyondspring Pharmaceuticals, Inc. Method of treating a brain tumor
US11918574B2 (en) 2015-03-06 2024-03-05 Beyondspring Pharmaceuticals, Inc. Method of treating cancer associated with a RAS mutation
US11389512B2 (en) 2015-06-22 2022-07-19 Ampio Pharmaceuticals, Inc. Use of low molecular weight fractions of human serum albumin in treating diseases
US11254657B2 (en) 2015-07-13 2022-02-22 Beyondspring Pharmaceuticals, Inc. Plinabulin compositions
US10912748B2 (en) 2016-02-08 2021-02-09 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US11857522B2 (en) 2016-02-08 2024-01-02 Beyondspring Pharmaceuticals, Inc. Compositions containing tucaresol or its analogs
US11229642B2 (en) 2016-06-06 2022-01-25 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing neutropenia
US11633393B2 (en) 2017-01-06 2023-04-25 Beyondspring Pharmaceuticals, Inc. Tubulin binding compounds and therapeutic use thereof
US11786523B2 (en) 2018-01-24 2023-10-17 Beyondspring Pharmaceuticals, Inc. Composition and method for reducing thrombocytopenia

Also Published As

Publication number Publication date
CA2141939A1 (en) 1994-03-03
ATE162186T1 (en) 1998-01-15
EP0672036A1 (en) 1995-09-20
AU4726593A (en) 1994-03-15
BG99495A (en) 1995-12-29
AU678172B2 (en) 1997-05-22
WO1994004512A1 (en) 1994-03-03
ZA935969B (en) 1995-02-16
CZ38195A3 (en) 1995-09-13
WO1994004513A1 (en) 1994-03-03
HU9500436D0 (en) 1995-04-28
PL307438A1 (en) 1995-05-29
ES2111169T3 (en) 1998-03-01
FI950616A (en) 1995-04-13
FI950617A (en) 1995-04-13
HUT71592A (en) 1996-01-29
BG99496A (en) 1995-12-29
GB2284420B (en) 1996-09-25
TW334427B (en) 1998-06-21
CZ38395A3 (en) 1995-10-18
CA2141938A1 (en) 1994-03-03
JPH08504176A (en) 1996-05-07
DK0655060T3 (en) 1998-02-09
IL106695A0 (en) 1993-12-08
KR950702967A (en) 1995-08-23
HUT71593A (en) 1996-01-29
GB2284420A (en) 1995-06-07
DE69316370T2 (en) 1998-07-16
SK19495A3 (en) 1995-11-08
FI950616A0 (en) 1995-02-13
SK19595A3 (en) 1995-09-13
AU693420B2 (en) 1998-07-02
HU9500437D0 (en) 1995-04-28
US5700804A (en) 1997-12-23
RU95108759A (en) 1996-12-10
KR950702968A (en) 1995-08-23
ZA935968B (en) 1995-02-16
EP0655060B1 (en) 1998-01-14
IL106696A0 (en) 1993-12-08
FI950617A0 (en) 1995-02-13
AU4726493A (en) 1994-03-15
RU95108387A (en) 1996-12-10
BR9306904A (en) 1998-12-08
GB9502859D0 (en) 1995-04-05
DE69316370D1 (en) 1998-02-19
GB9217331D0 (en) 1992-09-30
PL307437A1 (en) 1995-05-29
GR3026272T3 (en) 1998-06-30
JPH08504175A (en) 1996-05-07
BR9306905A (en) 1998-12-08

Similar Documents

Publication Publication Date Title
EP0655060B1 (en) Pharmaceutically active diketopiperazines
AU693159B2 (en) Pharmaceutical piperazine compounds
US5902812A (en) Pharmaceutical piperazine compounds
US5891877A (en) Pharmaceutical compounds
WO1995032190A2 (en) Pharmaceutical diketopiperazine compounds
US5852018A (en) Pharmaceutical piperazine compounds
EP1332131A2 (en) Acid derivatives useful as serine protease inhibitors
CN1235597A (en) Heterocycle derivatives inhibiting factor Xa
JP2000507588A (en) Amidinohydrazone as a protease inhibitor
EP0421861A1 (en) 2-Hydroxy thiophene- and furan derivatives condensed with a nitrogen containing ring, process for their preparation and their therapeutical application
CA2901576A1 (en) Albicidin derivatives, their use and synthesis
CN1284063A (en) Compounds
TW200825056A (en) New compounds
JP2003534308A (en) Novel MMP-2 / MMP-9 inhibitor
US5003070A (en) Substituted azacyclohexyl derivatives of rifamycins
CA2308780C (en) Novel derivatives of 2,3-methanoamino acids, process for their preparation and pharmaceutical compositions containing them
CN115850240B (en) Synthesis method of medicine ao Lu Taxi Ni for treating acute myelogenous leukemia
ZA200100238B (en) Bispiperidines as antithrombotic agents.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19950222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 19951018

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

REF Corresponds to:

Ref document number: 162186

Country of ref document: AT

Date of ref document: 19980115

Kind code of ref document: T

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

Representative=s name: PATENTANWAELTE SCHAAD, BALASS, MENZL & PARTNER AG

Ref country code: CH

Ref legal event code: EP

ITF It: translation for a ep patent filed

Owner name: RACHELI & C. S.R.L.

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REF Corresponds to:

Ref document number: 69316370

Country of ref document: DE

Date of ref document: 19980219

ET Fr: translation filed
REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2111169

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

Free format text: 78370

REG Reference to a national code

Ref country code: PT

Ref legal event code: SC4A

Free format text: AVAILABILITY OF NATIONAL TRANSLATION

Effective date: 19980320

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 19980806

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DK

Payment date: 19980813

Year of fee payment: 6

Ref country code: AT

Payment date: 19980813

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 19980814

Year of fee payment: 6

Ref country code: PT

Payment date: 19980814

Year of fee payment: 6

Ref country code: FR

Payment date: 19980814

Year of fee payment: 6

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19980816

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 19980819

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IE

Payment date: 19980820

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 19980821

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: MC

Payment date: 19980824

Year of fee payment: 6

Ref country code: CH

Payment date: 19980824

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: NL

Payment date: 19980827

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 19980831

Year of fee payment: 6

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: BE

Payment date: 19981016

Year of fee payment: 6

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed
GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 19980816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990816

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990816

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990816

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990817

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY

Effective date: 19990830

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990831

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990831

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990831

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990831

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 19990831

BERE Be: lapsed

Owner name: XENOVA LTD

Effective date: 19990831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000229

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000229

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000301

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000428

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

EUG Se: european patent has lapsed

Ref document number: 93918032.9

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20000301

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20000601

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20000229

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20000911

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.

Effective date: 20050816